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ABSTRACT
Smoak, Peter Royal. The Effects of Kefir and Exercise on Immune Function and Gut
Health. Published Doctor of Philosophy dissertation, University of Northern
Colorado, 2019.
Cancer is one of the most prevalent diseases affecting society today, and the
number of newly diagnosed cases increases every year. Unresolved inflammation is an
important underlying cause of cancer and chronically elevated concentrations of
inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and
C-reactive protein (CRP) are positively related to cancer incidence and progression.
Cancer treatments like chemotherapy and radiation therapy can impair beneficial gut
microbes that help to protect against pathogens and modulate immunity. Physical
activity and exercise regimens improve chronic inflammation and gut microbes in cancer
survivors but relatively few studies have explored the potential for nutrition to further
exacerbate the positive immunomodulating effects of exercise. Kefir is a fermented diary
product that contains a variety of probiotics and has the potential to help physically active
cancer survivors. However, the potential for kefir to improve chronic inflammation in
cancer survivors who are enrolled in a structured exercise program has not been explored.
The purpose of this study was to investigate the effects of 12 weeks of kefir
supplementation during a supervised structured exercise program in cancer survivors.
Nineteen cancer survivors 40 to 80-years-old who were enrolled in a structured exercise
program and had undergone chemotherapy or radiation therapy within the past two years
were separated into kefir (KEF) or control (CON) exercise treatment groups. All
iii

participants underwent 12 weeks of three days per week structured aerobic and resistance
exercise training and the kefir group drank eight ounces of kefir following each exercise
session. Each participant visited the test site three times at the pre-intervention time point
and three times at post-intervention time points in addition to the 12 weeks of exercise
training. Visits included assessments of body size and composition, aerobic fitness and
muscular strength, medical history, psychological state, dietary assessments, and blood
collection. Blood was analyzed for serum CRP, IL-6, and lipopolysaccharide (LPS)
concentrations, and stimulated with LPS in culture to evaluate whole blood IL-6 and
TNF-α production. Samples were prepared for flow cytometry analysis of monocyte
number and percentage as well as monocyte phenotype.
When both the KEF and the CON groups were combined, participants had high
body fat percentages (36.4 ± 8.1%) prior to the intervention; a time by group interaction
was observed where the KEF group experienced a significant 10.7% reduction in body fat
by the post-intervention time point (p = .019); no change was observed in the CON group
post-intervention. Furthermore, there was a main effect for time and a time by group
interaction observed in lean body mass where the CON group significantly improved lean
body mass (p = .002) but the KEF group improved lean body mass beyond the
improvement observed in the CON group (p = .014). A significant main effect for time
was observed where when both KEF and CON groups were combined, there were
significant improvements with respect to aerobic fitness (p = .0.001), chest press strength
(p = .027), lat pulldown strength (p = .000), and leg press strength (p = .015) at the postintervention time point. A main effect for time revealed improvements in scores on the
Beck Depression Inventory (p = .08), Piper Fatigue Scale (p = .002) and gastric distress
iv

survey (p = .013) when both KEF and CON groups were combined. In addition, a
significant time by group interaction was observed post-intervention where the KEF
group experienced reductions in fatigue (p = .002) and gastric distress (p = .021) beyond
that observed in the CON group. Additionally, a time by group interaction was observed
where the KEF group experienced significant reductions in serum concentrations of LPS
(p = .0137) and LPS stimulated IL-6 production (p = .034) by the pre-intervention time
point, while the CON group experienced no change. Furthermore, a significant main
effect for time was observed; when both KEF and CON groups were combined, there was
a significantly reduction in LPS-stimulated TNF-α production (p = .022). A significant
time by group interaction was observed in the KEF group where percent of monocytes
that were classical significantly increased (p = .016) and percent of monocytes that were
non-classical significantly decreased (p = .016) compared to the CON group by the postintervention time point. Moreover, a main effect for time was observed where when both
KEF and CON groups were combined, there was a significant reduction in the percent of
monocytes that were intermediate (p = .02) at the post-intervention time point.
Twelve weeks of supervised exercise training significantly improved VO2Peak,
muscular strength and lean body mass in all participants. In addition, a significant time
by group interaction was observed where the KEF group experienced a significant body
fat percent reduction and an increase in lean body mass when compared to the CON
group. Both the kefir group and exercise control significantly improved depression and
fatigue by the end of the exercise intervention while the kefir group improved fatigue
beyond that of exercise control. Moreover, both groups significantly improved gastric
distress over the course of the intervention but kefir supplementation resulted in a greater
v

reduction in GI distress. Both the kefir and control groups experienced reductions in
stimulated Il-6 production per monocyte by the post-intervention time point and kefir
supplementation reduced overall stimulated IL-6 production beyond the reduction
observed in the control group. Furthermore, both groups experienced reductions in
stimulated TNF-α by the post-intervention time point. While it has been established that
exercise training could help to improve many aspects of the lives of cancer survivors,
kefir appeared to be well-tolerated and had the potential to improve immune function and
fatigue beyond the benefits of a chronic exercise intervention alone. Including nutritional
support with kefir as a post exercise nutrition strategy might be what cancer rehabilitation
programs should consider in the future.
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CHAPTER I
INTRODUCTION
Cancer is one of the most prevalent diseases affecting society today. It is
predicted that from 2010 to 2020, the number of cancer cases will increase by more than
20%, translating to approximately 1.9 million cases diagnosed each year (Siegel, Miller,
& Jemal, 2018). An important underlying cause of cancer is unresolved inflammation,
which has been named as the seventh addition to the Hallmarks of Cancer (Hanahan &
Weinberg, 2011). Furthermore, chronically elevated concentrations of inflammatory
cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and C-reactive
protein (CRP) are correlated with inflammatory diseases such as cancer and
cardiovascular disease (Kumari, Dwarakanath, Das, & Bhatt, 2016; Zhang & An, 2007;
Zulet, Puchau, Navarro, Martí, & Martínez, 2007).
Monocytes are part of the innate immune response that plays an important role in
the initiation of inflammation in the body, especially in the presence of pathogenic
bacteria (Uronen et al., 2000). Tumor cells can stimulate the production of monocytes as
well as induce differentiation into tumor-associated macrophages (TAMs), which can
have tumor protective and proliferative effects (Komohara, Fujiwara, Ohnishi, & Takeya,
2016; Ostuni, Kratochvill, Murray, & Natoli, 2015). The use of some chemotherapies can
cause monocyte to differentiate into TAMs and promote tumor progression (Dijkgraaf et
al., 2013).
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Monocytes are categorized into three subsets based on the presence of a coreceptor (CD14) and the FcγRIII receptors (CD16; Bradfield et al., 2007; Randolph,
Sanchez-Schmitz, Liebman, & Schäkel, 2002): (a) classical monocytes (CD14++CD16−)
make up 80-95% of all monocytes and tend to be less inflammatory unless stimulated
(Bradfield et al., 2007; Randolph et al., 2002); (b) intermediate monocytes
(CD14++CD16+) are approximately 2-11% \ of all monocytes and have characteristics
similar to both of the other subtypes (Wong et al., 2011); and, (c) nonclassical
(inflammatory) monocytes (CD14+CD16++) are 2-8% of all monocytes and are
responsible for patrolling and clearing damaged extravascular tissue (Auffray et al., 2007;
Carlin et al., 2013; Shi & Pamer, 2011). Elevated numbers of inflammatory monocytes
are associated with tumor cell survival and cancer metastasis (Tacke et al., 2007).
Monocytes express a wide array of pathogen recognition receptors (PRRs) that allow
them to initiate defense against invading pathogens such as bacteria, fungi, and
viruses(Akira, Uematsu, & Takeuchi, 2006; Janeway & Medzhitov, 2002; Kawai &
Akira, 2010). Lipopolysaccharide (LPS), a gram-negative bacterial endotoxin (Wellen &
Hotamisligil, 2003), can activate a toll-like receptor 4 (TLR4) that stimulates downstream
signaling, resulting in the production of inflammatory cytokines (Bagchi et al., 2007).
The gut microbiome is an aggregate of microorganisms living within the
gastrointestinal tract with the majority residing in the colon (Lozupone, Stombaugh,
Gordon, Jansson, & Knight, 2012; Sender, Fuchs, & Milo, 2016). These microbes play a
role in the development of the immune system as well as in mediating whole body
immune system function (Lozupone et al., 2012; Sender et al., 2016). Although this
work is still in its infancy, there are also studies exploring the link between the health of
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the gut microbiome to chronic inflammation and the incidence of cancer and the efficacy
of cancer treatments (Sheflin, Whitney, & Weir, 2014; N. Singh et al., 2014; Vétizou et
al., 2015).
Many pharmacological cancer treatments are effective at slowing cancer
development and progression; yet, they are often associated with significant negative side
effects. More specifically, chemotherapy and radiation therapy are two of the most
effective and commonly used cancer treatments; however, both are associated with
chronic, systemic inflammation and major disturbances of the microbiome (Grivennikov
et al., 2012). Currently, research is limited with respect to the duration of chemotherapy
and radiation’s effects on the microbiome. Following chemotherapy and radiotherapy
treatment, the diversity and number of commensal bacteria decrease significantly and the
number and type of pathogenic bacteria increase. This imbalance between the gut
microbiota and the host is referred to as gut dysbiosis (Lozupone, 2016; Montassier et al.,
2014), which is linked to the development of an inflammatory condition known as
mucositis. Mucositis is the ulceration and deterioration of the gut barrier (Blijlevens,
Donnelly, & De Pauw, 2000; Vera-Llonch, Oster, Ford, Lu, & Sonis, 2007). When the
integrity of the intestinal barrier and/or microbiome is compromised, the risk of tissue
malignancy is increased (Sheflin et al., 2014). Consequently, some microbes can
translocate from the gut and enter the tumor microenvironment, thereby eliciting cancerpromoting effects that might reduce the efficacy of anticancer drugs (Sheflin et al., 2014;
Vétizou et al., 2015). Although chemotherapy has the most deleterious to commensal gut
bacteria, many other types of drugs and treatments have negative side effects as well
(Carmody & Turnbaugh, 2014; Kwok et al., 2012; Montassier et al., 2014).
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Research suggested a healthy gut microbiome might increase the effectiveness of
certain chemotherapies (Nelson, Diven, Huff, & Paulos, 2015; Sivan et al., 2015; Vétizou
et al., 2015). Dairy products can play a role in the composition and health of the gut
microbiome (Bassaganya-Riera et al., 2004). Polyunsaturated fats such as conjugated
linoleic acid (CLA) found in dairy products have several health benefits associated with
them (Bassaganya-Riera et al., 2004). The adult microbiome does not have a large
number of genes involved in fatty acid metabolism (Kurokawa et al., 2007); however,
interactions between polyunsaturated fats and some probiotics in the microbiota could
affect biological roles in both (Kankaanpää, Salminen, Isolauri, & Lee, 2001).
Additionally, gut microbes could alter and modify polyunsaturated fat metabolism to
produce CLA and increase the production of short-chain fatty acids (SCFAs; Wall et al.,
2012). Unfortunately, many individuals with cancer cannot tolerate dairy products and;
therefore, are not able to experience some of the potential benefits (Kim, 2017; Osterlund
et al., 2004).
Kefir is a naturally fermented milk beverage containing a large population of a
mixed microbial culture including lactic acid bacteria and yeasts (Garofalo et al., 2015).
Kefir differs from other fermented milk products in its unique starter culture, which is an
aggregation of many different bacteria and yeast species bound together in an
exopolysaccharide (EPS) matrix produced by lactic acid bacteria in the presence of yeast.
Kefir produced in the traditional manner, utilizing the unique mother culture as the source
of probiotics, could contain over one trillion colony-forming units per gram (CFU/g),
which is much higher than the amount of live and active bacteria typically in commercial
yogurt (100 million CFU/g) and probiotic pills (no more than 10 billion CFU/capsule;
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Garofalo et al., 2015). In addition to the direct action of probiotics on host health, kefir
contains naturally occurring metabolic by-products of bacterial and yeast fermentation
such as biologically active peptides, exopolysaccharides, and organic acids that are also
thought to play important roles in the protective effects and immune system regulation
demonstrated by kefir ingestion (Garofalo et al., 2015). Furthermore, kefir has been
shown to reduce deoxyribonucleic acid (DNA) damage that causes cancer, reduce the
proliferation of cancer cells, and induce pro-apoptotic effects in cancer cells (Grishina et
al., 2011; Maalouf, Baydoun, & Rizk, 2011; Rizk, Maalouf, & Baydoun, 2009).
Purpose
The overall goal of this study was to explore the effects of 12 weeks of kefir
consumption on circulating biomarkers of inflammation (IL-6 and CRP), a biomarker of
gut dysbiosis (LPS), and monocyte phenotype and function in active cancer survivors.
These results were compared to a similar group of non-kefir consuming cancer survivors.
Specific Aims and Hypotheses
A1

Explore the effects of 12 weeks of kefir consumption on biomarkers of
inflammation in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.

H1

Inflammatory biomarkers (IL-6 and CRP) will be reduced with 12 weeks
of kefir consumption in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.

A2

Explore the effects of 12 weeks of kefir consumption on circulating
monocyte phenotype in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.

H2

Total percent of immune cells that are monocytes and the percent of
inflammatory monocytes will be reduced after 12 weeks of kefir
consumption in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.
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A3

Explore the effects of 12 weeks of kefir consumption on monocyte
function in active cancer survivors who have undergone chemotherapy
and or radiation therapy within the past two years.

H3

Monocyte response to an LPS stimulus will be reduced as defined by
measures of IL-6 and TNF-α production in cell culture after 12 weeks of
kefir consumption in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.

A4

Explore the effects of 12 weeks of kefir consumption on circulating
concentrations of LPS in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.

H4

Circulating serum concentrations of LPS will be reduced after 12 weeks of
kefir consumption in active cancer survivors who have undergone
chemotherapy and or radiation therapy within the past two years.

A5

Explore the relationships between body size and composition, biomarkers
of inflammation, biomarkers of gut dysbiosis, dietary habits, and
monocyte phenotype and function in active cancer survivors who have
undergone chemotherapy and or radiation therapy within the past two
years.

H5

Significant positive correlations will be observed between biomarkers of
inflammation and body size and composition, biomarkers of inflammation
and monocyte phenotypes, inflammatory monocytes and body
composition, and biomarkers of gut dysbiosis and monocyte phenotype.
Additionally, negative correlations will be observed between fermented
food consumption and gut dysbiosis and dairy consumption and body
composition in active cancer survivors who have undergone chemotherapy
and or radiation therapy within the past two years.
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CHAPTER II
REVIEW OF LITERATURE
Introduction
Unresolved chronic, systemic inflammation is directly associated with the
development and progression of cancer (Hanahan & Weinberg, 2011). Biomarkers such
as IL-6, TNF-α, and CRP are well-established biomarkers of inflammation (Zhang & An,
2007) and treatments for cancer such as chemotherapy and radiation therapy significantly
increase them (Zulet et al., 2007). These cancer treatments are extremely detrimental to
the gut microbiome and could lead to mucositis, gut dysbiosis, increased gut
permeability, and an exacerbated immune response, resulting in an increase in systemic
inflammation. Moreover, the microbes in the gut play a key role in how the body
responds to chemotherapy and radiation treatment (Alexander et al., 2017; Nelson et al.,
2015; Viaud et al., 2013; Vétizou et al., 2015). Probiotics could help improve the health
of the gut microbiome and reverse gut dysbiosis and symptoms associated with it (Butel,
2014). This literature review explored the role of inflammation, monocyte phenotype and
function, as well as the gut microbiome and the potential for kefir to improve cancer
survivor health. Additionally, because this project involved physically active cancer
survivors, sections are included that address the influence of exercise on the immune
system and gut health.
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Inflammation
Inflammation is an important immune response elicited by the body in times of
injury, sickness, stress, or traumatic events. This response is designed to eliminate these
threats and is characterized by the production of cytokines from both immune and nonimmune cells, which, in turn, act to further mediate the inflammatory response (Zulet et
al., 2007). An appropriate inflammatory response is important to maintain homeostasis.
An inflammatory response can be characterized by both the magnitude and duration of
the response. A diminutive inflammatory response can result in increased susceptibility
to tissue destruction by harmful stimuli such as bacteria, viruses, or other microbes
(Pahwa, 2018). On the other hand, an exacerbated inflammatory response could cause
unintended cellular damage (Pahwa, 2018). An acute inflammatory response could arise
from injury, sickness, stress, or even an intense bout of exercise, and could last a few
hours to a few days. Chronic inflammation is long-term, unresolved inflammation for
prolonged periods of time that could range from several months to years (Pahwa, 2018).
Chronic, systemic inflammation is associated with the development and
progression of cancer (Kaptoge et al., 2010; Pahwa, Kumar, & Das, 2016; Zulet et al.,
2007) and it is evident an inflammatory microenvironment is an essential component of
all tumors (Mantovani, Allavena, Sica, & Balkwill, 2008). An inflammatory tumor
microenvironment could intensify mutation rates as well as enhance the proliferation of
mutated cells. Reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI)
produced by inflammatory cells are capable of inducing DNA damage and genomic
instability (Kraus & Arber, 2009). Additionally, inflammatory cytokines such as IL-6
and TNF-α are known to promote tumor production and survival (Becker et al., 2004;
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Grivennikov et al., 2009; Park et al., 2010). Furthermore, the relationship between
inflammation and tumor initiation works both ways. Inflammation caused by DNA
damage could lead to inflammation and, in so doing, promote tumorigenesis (Mantovani
et al., 2008).
Inflammatory Biomarkers
Inflammatory biomarkers are helpful in evaluating the inflammatory status of
individuals. These biomarkers can be measured in individual tissues as well as in urine,
saliva, and circulating in the blood and cerebrospinal fluid (Brenner et al., 2014). The
most commonly studied circulating inflammatory biomarkers are cytokines and CRP.
Cytokines are a large group of over sixty glycoproteins secreted by immune cells,
adipocytes, hepatocytes, and skeletal muscle (myokines), and could mediate immunity,
inflammation, and hematopoiesis (Zhang & An, 2007). The term cytokine is used to
generally identify these proteins and some areas of study further describe cytokines based
on the cells that produce them. For instance, lymphokines are produced by lymphocytes,
monokines are produced by monocytes, and interleukins are secreted by leukocytes to act
on other leukocytes as well as other tissues (Zhang & An, 2007). Some cytokines are
produced by several immune cell types; while others are produced by only a few and
could have autocrine, paracrine, or endocrine actions. Cytokines can be separated into
two categories based on their proinflammatory or anti-inflammatory actions; two
commonly studied pro-inflammatory cytokines include IL-6 and TNF-α (Dandona,
Aljada, & Bandyopadhyay, 2004; Zhang & An, 2007).
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Interleukin 6
One of the most commonly studied inflammatory biomarkers is IL-6, a cytokine
produced by monocytes and macrophages as well as T and B lymphocytes (Steensberg et
al., 2002). This cytokine is frequently viewed as proinflammatory with functions similar
to those of tumor TNF-α and interleukin-1 β (IL-1β) (Steensberg et al., 2002). Normal
resting concentrations of IL-6 in healthy individuals are approximately 0.7 pg/mL;
however, during times of infection, disease, trauma, and even during prolonged bouts
exercise, concentrations can be as high as 300 pg/mL (Fischer, 2006; Ostrowski, Rohde,
Asp, Schjerling, & Pedersen, 1999). Additionally, IL-6 is also one of the most abundant
cytokines associated with acute inflammatory conditions and chronically elevated
concentrations are associated with diseases such as cancer and diabetes (Nishimoto &
Kishimoto, 2008).
When IL-6 is produced by immune cells in response to TNF-α via the nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, it acts in an
inflammatory manner. However, when IL-6 is produced as a myokine from the working
skeletal muscle during exercise and following prolonged exercise (Pedersen & Febbraio,
2008), it acts independently of binding circulating inflammatory ligands and exerts its
actions through calcium signaling and the MAPK pathways (Brandt & Pedersen, 2010).
Additionally, elevated IL-6 concentrations produced by skeletal muscle initiate the
secretion of interleukin 1 receptor agonist (IL-1RA)and interleukin 10 (IL-10) from
monocytes (Steensberg, Fischer, Keller, Møller, & Pedersen, 2003). This action causes
an anti-inflammatory effect, can improve vascular reactivity and lipid and glucose
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metabolism, and induce the suppression of pro-inflammatory cytokine production
(Pedersen, Akerström, Nielsen, & Fischer, 2007; Pedersen et al., 2003).
Overproduction of IL-6 is commonly observed in a variety of cancer cells and
elevated serum IL-6 concentrations are associated with poor outcomes in cancer patients
(Gao et al., 2007; Sansone et al., 2007). Additionally, mutations in tumors often target
IL-6 signal transduction components, leading to the activation of signal transducer and
activator of transcription 3 (STAT3; Rebouissou et al., 2009). Both IL-6 and STAT3
signaling are essential for cancer development in the liver, lungs, mammary glands,
intestinal epithelium, and the hematopoietic compartment (Gao et al., 2007; Rebouissou
et al., 2009; Reynaud et al., 2011; Sansone et al., 2007). This becomes apparent in cases
of chemotherapy-resistance where the presence of IL-6 is crucial for both the
maintenance and progression of residual tumor cells (Gilbert & Hemann, 2010). For
example, endothelial cells treated with the chemotherapy doxorubicin release IL-6 and
promote the induction of the pro-survival gene B-cell lymphoma-extra-large (Bcl-xL) in
proximal lymphoma cells (Gilbert & Hemann, 2010). Consequently, pro-apoptotic
signaling induced by chemotherapy on tumor cells is countered by anti-apoptotic
signaling stemming from the tumor microenvironment (Gilbert & Hemann, 2010).
Furthermore, chemotherapy treatments such as doxorubicin and cisplatin can
increase IL-6 production and increase the release of free fatty acids into the blood. The
increased concentration of circulating fatty acids can cause further activation of immune
cells like monocytes and macrophages (Elsea, Roberts, Druker, & Wood, 2008). This can
lead to chronic inflammation and the potential for the development of secondary
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inflammation-related diseases such as diabetes and cardiovascular disease (Elsea et al.,
2008).
Tumor Necrosis Factor-α
An additional inflammatory biomarker of importance is TNF-α. This cytokine is
an inflammatory cytokine produced by several types of leukocytes including monocytes
and macrophages (Pavese et al., 2010). The effects of TNF-α involve inducing
inflammation as well as stimulating the production of other inflammatory biomarkers
including IL-6, IL-8, and C-reactive protein. Furthermore, TNF-α plays a more
complicated role in cancer cell death and survival (Pavese et al., 2010).
In inflammatory conditions, TNF-α binds to the tumor necrosis factor receptors 1
(TNFR1) and 2 (TNFR2), inducing the activation and upregulation of the NF-κB
pathway (Bhattacharyya, Dudeja, & Tobacman, 2010). Almost every tissue in the body
expresses TNFR1 while only immune cells express TNFR2 (Chen & Goeddel, 2002).
Activation of the NF-κB pathway increases the production of cytokines including IL-1β,
IL-6, and interleukin-8 (IL-8) (Kant et al., 2011). In addition to activation of the NF-κB
pathway, TNFR1 and TNFR2 also activate the MAPK pathway, which is associated with
the production of inflammatory cytokines such as interferon-γ (IFN-γ), interleukin-4 (IL4) and, TNF (Kant et al., 2011).
During homeostasis, normal circulating TNF-α concentrations are approximately
2 pg/mL (Pavese et al., 2010). This cytokine stimulates direct pathways that regulate cell
death, survival, and proliferation (Wang & Lin, 2008). Elevated concentrations of TNFα are associated with increased cancer progression and mortality in addition to the
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development of cardiovascular disease and dementia (Bruunsgaard, Andersen-Ranberg,
Hjelmborg, Pedersen, & Jeune, 2003).
The anticancer properties of TNF-α are primarily accomplished by binding to the
tumor TNFR1, which acts as death receptor and induces cancer cell death. However,
increased TNF-α expression in pre-cancerous and tumor cells is associated with
progression of malignant diseases such as chronic lymphocytic leukemia, prostate cancer,
breast cancer, and cervical carcinoma (García-Tuñón et al., 2006; Michalaki, Syrigos,
Charles, & Waxman, 2004). These responses are due to TNF stimulating tumor
proliferation, survival, migration, and angiogenesis in cancer cells resistant to TNFinduced cytotoxicity (Wang & Lin, 2008).
C-Reactive Protein
A commonly studied biomarker of inflammation is CRP, an acute-phase protein,
which is synthesized primarily in liver hepatocytes but can also be produced by smooth
muscle cells, macrophages, endothelial cells, lymphocytes, and adipocytes (Calabro,
Chang, Willerson, & Yeh, 2005; Volanakis, 2001). This important inflammatory
biomarker is commonly used by clinicians to assess systemic inflammation and as a risk
factor for cardiovascular disease (CVD, Zulet et al., 2007). In normal resting conditions,
CRP is bound to two carboxylesterases—glycoprotein 60a (gp60a) and glycoprotein 50b
(gp50b)—in the endoplasmic reticulum in the liver and is slowly released from the
endoplasmic reticulum (Du Clos & Mold, 2004). However, following an increase in
inflammatory cytokine concentrations, CRP becomes released from gp60a and gp50b.
Consequently, CRP is rapidly secreted from the liver (Du Clos & Mold, 2004).
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The average CRP concentration in healthy individuals is approximately 0.8 mg/L;
however, this could be altered by many factors including age, gender, weight, lipid
concentrations, blood pressure, and smoking status (Devaraj, Venugopal, & Jialal, 2006;
Hage & Szalai, 2007). Serum concentrations above 2.0 mg/L are considered elevated
while values below 1.0 mg/L are desirable and considered to be low risk for
cardiovascular events (Church et al., 2010; Ridker, 2003). Additionally, an individual
with a CRP concentration higher than 3 mg/L has an increased risk of coronary heart
disease (Kushner, 1990) and this risk increases in those with type 2 diabetes (Soinio,
Marniemi, Laakso, Lehto, & Rönnemaa, 2006).
Inflammatory conditions such as rheumatoid arthritis, cardiovascular diseases, as
well as infection could elicit elevated concentrations of CRP (Du Clos & Mold, 2004).
During these disease states and times of immune response, CRP concentrations could
increase by 25% while bacterial infections could induce the greatest concentration
increase with CRP with some bacteria increasing concentrations up to 1,000 times higher
than resting (Thompson, Pepys, & Wood, 1999). Additionally, with severe tissue
damage or progressive cancer, CRP concentrations could increase from approximately
0.05 mg/mL to over 500 mg/mL within 24–72 hours (Ciubotaru, Potempa, & Wander,
2005). Synthesis of CRP is stimulated in response to proinflammatory cytokines and IL6 is considered to be the main inducer of CRP expression in liver hepatocytes (Szalai et
al., 1998). Expression of CRP by the liver could also be elicited by IL-1 and TNF-α, but
to a much lesser extent, and could be considered more of a CRP enhancer.
The primary role of CRP in inflammation tends to focus on the activation of the
complement component 1q (C1q) molecule in the complement pathway, which leads to
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the opsonization of pathogens. In addition to CRP’s ability to initiate the fluid phase
pathways of the host defense by activating the complement pathway, it can also initiate
cell-mediated pathways via complement activation as well binding to immunoglobulin G
(IgG) Fc receptors (Pradhan, Manson, Rifai, Buring, & Ridker, 2001), which leads to the
release of pro-inflammatory cytokines (Du Clos, 2000).
Monocytes
Monocytes are a part of the mononuclear phagocyte system (MPS), a specialized
phagocytic system, continuously derived from hematopoietic stem cells in the adult bone
marrow through several developmental steps called hematopoiesis or monopoiesis.
Following these steps, they enter the peripheral blood and make up approximately 1015% of peripheral blood leukocytes (Geissmann et al., 2010; Lambert, Preijers,
Yanikkaya Demirel, & Sack, 2017; Patel et al., 2017; Wacleche, Tremblay, Routy, &
Ancuta, 2018). Monopoiesis is tightly regulated by microenvironmental cues,
modulating gene expression in developing cells and leading to the often irreversible
phenotypic and functional changes associated with hematopoietic differentiation (Fogg et
al., 2006). Monocytes contain a wide array of pathogen recognizing receptors (MonguióTortajada, Franquesa, Sarrias, & Borràs, 2018) and are critically involved in processes
such as innate immune functions, support of adaptive immunity, and tissue homeostasis
(Geissmann et al., 2010; Tacke & Randolph, 2006). These immune cells are essential to
a coordinated immune response because they are recruited to the site of inflammation and
perpetuate the cycle of inflammation by releasing inflammatory cytokines (Shi & Pamer,
2011).
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Despite what their “mono” prefix might suggest, circulating monocytes are a
dynamic and highly plastic population of immune cells. To date, three distinct,
recognized subsets are defined by the differences in phenotype, size, morphology, and
transcriptional profiles (Ziegler-Heitbrock et al., 2010). In humans, monocytes are
identified by their expression of cluster of differentiation 14 (CD14) and can be further
characterized by the degree to which CD14 and CD16 are expressed on the cell surface.
Human monocytes can be separated into three subsets: classical, intermediate, and nonclassical (Ziegler-Heitbrock et al., 2010). In healthy individuals, approximately 80-95%
of the monocyte pool consists of classical monocytes while the remaining 5 to 15%
consists of intermediate (2-11%) and non-classical monocytes (2-8%; Seidler,
Zimmermann, Bartneck, Trautwein, & Tacke, 2010).
Classical monocytes (CD14++ CD16−) are the only subtype of monocyte found
in the bone marrow. This population expresses high concentrations of CD14 but lacks
CD16 on the cell surface. Classical monocytes possess high concentrations of the C-C
chemokine receptor type 2 (CCR2) and low concentrations of the CX3C chemokine
receptor 1 (CX3CR1; Seidler et al., 2010; Ziegler-Heitbrock et al., 2010). Increased
expression of CCR2 allows them to be more efficiently attracted to chemokine C-C motif
ligand 2 (CCL2) or monocyte chemoattractant protein 1 (MCP1) than other monocyte
subsets (Ancuta et al., 2003). Classical monocytes have a higher capacity to secrete IL-6
and lower capacity to secrete TNF-α than the other monocyte subsets. Classical
monocytes are also the only monocyte subset that possesses the ability to reverse
transmigrate out of the tissue (Bradfield et al., 2007; Randolph et al., 2002).
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The intermediate (CD14++ CD16+) monocyte subset shares phenotype and
functional characteristics with both the classical and non-classical monocytes; however,
they are more closely related to the non-classical subset (Wong et al., 2011).
Intermediate monocytes express high concentrations of CD14, low concentrations of
CD16, as well as moderate concentrations of CCR2 and high concentrations of CX3CR1
chemokine receptors on the cell surface. This subtype stays in circulation and can rapidly
produce proinflammatory cytokines such as IL-6, TNF-α, and IL-1β in response to
damage or infection (Ancuta, Wang, & Gabuzda, 2006; Cros et al., 2010; Yang, Zhang,
Yu, Yang, & Wang, 2014). Additionally, they are able to phagocytize microparticles
(Yang, Zhang et al., 2014), migrate to lymph nodes to present antigens, and are supported
by their high expression of human leukocyte antigen–DR isotype (HLA-DR; Lund,
Boysen, Åkesson, Lewandowska-Sabat, & Storset, 2016; Yang, Zhang et al., 2014;
Zawada et al., 2011). These monocytes are often referred to as “inflammatory”
monocytes (Wong et al., 2011). Some agree intermediate monocytes play a role in
inflammatory diseases including sepsis, rheumatoid arthritis, type 2 diabetes,
atherosclerosis, coronary heart disease, and cancer survival and metastasis (Belge et al.,
2002; Merino et al., 2011; Ziegler-Heitbrock, 2007).
Non-classical (CD14+ CD16++) monocytes, also known as patrolling monocytes,
express low concentrations of CD14 and high concentrations CD16 as well as low
concentrations of CCR2 and high concentrations of CX3CR1 chemokine receptors. Nonclassical monocytes can move along the endothelium and into damaged and inflamed
tissue (Auffray et al., 2007; Carlin et al., 2013). This action helps maintain the integrity
of the vasculature by clearing damage endothelial cells (Auffray et al., 2007; Carlin et al.,
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2013). Although non-classical monocytes function similarly to macrophages and are
referred to by some as vasculature macrophages, they cluster together with other
monocytes and do not express the core, mature macrophage signature (Gautier et al.,
2014; Jakubzick et al., 2013).
The three monocyte subtypes develop and differentiate linearly, converting from
classical to intermediate monocytes and then from intermediate to non-classical
monocytes (Mukherjee et al., 2015). During normal resting conditions, classical
monocytes are the first to appear in the blood and are thought to typically circulate for
approximately 24 hours. Following this period, classical monocytes either differentiate
or are cleared from circulation by extravasation or death. Classical monocytes that have
not entered the tissue and survived transition into intermediate monocytes. Intermediate
monocytes have some of the abilities of both classical and non-classical monocytes and
typically survive approximately four days. The intermediate monocytes then mature into
non-classical monocytes that survive for approximately seven days (Mukherjee et al.,
2015; Patel et al., 2017).
Additionally, despite what was once thought, circulating monocytes are not the
precursors to all tissue macrophages. Instead, during normal resting conditions,
macrophages are replenished from progenitors established during fetal development and
independent of monocytes (Epelman et al., 2014; Ginhoux et al., 2010; Jakubzick et al.,
2013; Yona et al., 2013). Moreover, monocytes have the ability to enter resting tissues,
patrol extravascular tissues, and pick up antigens for transport to lymph nodes while
remaining relatively undifferentiated instead of committing to macrophages or dendritic
cells (Jakubzick et al., 2013).
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In contrast, under inflammatory conditions, monocyte populations can drastically
change, which could include an increase in all monocyte subtypes or in specific subtypes,
depending on the type of infection or disease signals received (Patel et al., 2017).
Monocytes recruited to the inflamed tissue could differentiate into macrophages or
dendritic cells, depending on signals received by the tissue (Jakubzick et al., 2013). In
situations involving major systemic inflammation, there is a large loss of monocytes,
referred to as monocytopenia, and is usually followed by a rapid recovery of population
numbers (Cros et al., 2010; Patel et al., 2017).
Lipopolysaccharide and Monocyte Activation
Monocytes are an important part of innate immunity and are equipped with a wide
array of pattern recognition receptors (PRRs), which allow them to initiate defense
against invading pathogens. Toll-like receptors (TLRs) located in the cell membrane and
endosomal compartments are PRRs that sense different structural components expressed
by microorganisms such as bacteria, fungi, and viruses, known as pathogen-associated
molecular patterns (Akira et al., 2006; Janeway & Medzhitov, 2002; Kawai & Akira,
2010). There are 10 types of TLRs in humans, ranging from TLR1 through TLR10
(Mahla, Reddy, Prasad, & Kumar, 2013).
Depending on the type of ligand encountered, activation of toll-like receptors
triggers antimicrobial and inflammatory activities in a variety of tissues and cells. Tolllike receptor 4 (TLR-4) is found on a number of immune cells including monocytes,
macrophages, neutrophils, myeloid dendritic cells, mast cells, B cells, and intestinal
epithelium; it acts to recognize gram-negative bacteria in a partially direct and indirect
manner (Cario et al., 2000; Sabroe, Dower, & Whyte, 2005; Sallusto & Lanzavecchia,
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2002). This receptor is most well-known for its ability to bind the ligand
lipopolysaccharide (LPS), which is a gram-negative bacterial endotoxin (Wellen &
Hotamisligil, 2003). The three main components of LPS include lipid A, a core
oligosaccharide, and an O side chain (Raetz & Whitfield, 2002). Recognition of LPS
occurs through a series of interactions with several proteins including LPS binding
protein (LBP), CD14, lymphocyte antigen 96 (MD-2), and TLR4 (Gioannini & Weiss,
2007; Miyake, 2007). Normally, LPS is attached to the gram-negative bacterial
membrane; however, during an infection, it could become detached and taken up by LBP
in the blood or extracellular fluid. Lipopolysaccharide binding protein is a soluble shuttle
protein that directly binds to LPS and transfers it to monocyte CD-14, which can act as a
phagocytic receptor on its own or as an accessory protein for TLR-4 in the presence of
LPS (Murphy, Travers, Walport, & Janeway, 2008; Tobias, Soldau, & Ulevitch, 1986;
Wright, Tobias, Ulevitch, & Ramos, 1989). Then CD14 facilitates the transfer of LPS to
the TLR4/MD-2 receptor complex (Hailman et al., 1994). Lymphocyte antigen 96 binds
to TLR4 within the cell and acts to aid in LPS recognition as well as direct TLR4 to the
cell surface. When the TLR4/MD-2 complex encounters LPS, five of the six lipid chains
bind to MD-2 rather than TLR4. The last lipid chain, and part of the LPS backbone,
binds to TLR-4, which induces activation of the intracellular signaling pathways (Murphy
et al., 2008).
When toll-like receptors are activated by an antigen, TLRs can follow two main
signaling pathways: the myeloid differentiation factor 88 (MyD88)-dependent pathway or
the myeloid differentiation factor 88 (MyD88) independent pathway (Ullah, Sweet,
Mansell, Kellie, & Kobe, 2016). The MyD88-dependent pathway is used by all TLRs
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except TLR3 and leads to early activation of NFκB for inflammatory cytokine
production, especially TNF-α by monocytes. The MyD88-independent pathway is used
by viral dsRNA-sensing TLR3 and TLR4 to produce type-I interferon (IFN) as an
antiviral innate response (Bagchi et al., 2007). Interestingly, evidence suggested that
LPS-sensing TLR4 is the only TLR to signal through both pathways (Bagchi et al.,
2007).
Monocytes and Cancer
The largest reservoir of monocytes is the bone marrow where they are primarily
produced under normal resting conditions; however, monocytes can also be found in the
blood and spleen (Cortez-Retamozo et al., 2012; Robbins et al., 2012). Cancer can
change many characteristics of myeloid cells including alternating migratory and
functional properties and location of development (Cortez-Retamozo et al., 2012;
Robbins et al., 2012). In inflammatory conditions such as cancer, monocytes can also be
produced by extra-medullary hematopoiesis in the spleen (Cortez-Retamozo et al., 2012;
Robbins et al., 2012).
Bone marrow can partially outsource the production of myeloid cells to extramedullary sites in cancer (Cortez-Retamozo et al., 2012). A study examining the
alteration in myeloid development in a model of lung adenocarcinoma driven by
activation of K-Ras and inactivation of p53 showed hematopoietic stem cells moved into
the spleen and locally produced monocytes and granulocytes that contributed to tumor
growth (Cortez-Retamozo et al., 2012). Chemotactic signals elicit mobilization of
monocytes from the bone marrow and spleen, recruit them to target tissues, and induce
further differentiation (Shi & Pamer, 2011). Monocyte subsets express different
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quantities of the chemokine receptors CCR2 and CX3CR1. Consequently, monocyte
subsets have different migratory properties (Geissmann, Jung, & Littman, 2003).
Chemokine CCL2 was identified as the first tumor-derived factor (TDF) produced by
tumor cells that induced chemotaxis in monocytes (Bottazzi et al., 1983) and is currently
recognized as the major TDF responsible for recruiting circulating monocytes into a
variety of tumors (Pollard, 2004; Sica et al., 2012). Chemokine CCL2 is also produced
by tumors, can recruit CCR2-expressing inflammatory monocytes to the tumor site, and
elicit extravasation and tumor growth and progression (Qian et al., 2011).
Although CCL2 is the major TDF responsible for monocyte recruitment, several
other TDFs are associated with recruitment of monocytes to the target site and
differentiation. These TDFs include chemokines such as CCL3, CCL4, CCL5, and
CXCL12; and various growth factors including macrophage colony-stimulating factor
(M-CSF), transforming growth factor-α (TGF-α), fibroblast growth factor (FGF),
angiopoietin-2 (Ang-2), and vascular endothelial growth factor (VEGF; De Palma &
Naldini, 2009; Joyce & Pollard, 2009; Sica & Bronte, 2007; Sica et al., 2012). When
monocytes are recruited to the tumor sites by TDFs, they differentiate into tumorassociated macrophages (TAMs; Gabrilovich, Ostrand-Rosenberg, & Bronte, 2012), a
class of immune cells present in high numbers in the microenvironment of solid tumors
and strongly involved in cancer-related inflammation and tumor cell survival and
progression (Komohara et al., 2016; Ostuni et al., 2015).
Proliferation and survival of tumor cells can be induced by TAMs production and
release of trophic and activating factors including endothelial growth factor (EGF), FGF,
VEGF, platelet-derived growth factor (PDGF), and transforming growth factor-β (TGF-β;
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Lin et al., 2007; Mantovani et al., 2008; Sica et al., 2012). Additionally, TAMs secrete
proteolytic enzymes that degrade the extracellular matrix (ECM) and facilitate the
diffusion of growth factors in the tumor microenvironment (Joyce & Pollard, 2009;
Mantovani et al., 2008). As tumors grow and metabolic demand increases, there is a
need for improved and increased vascular structure to the tumor. Tumor angiogenesis
can be induced by almost all TAMS; however, it appears tyrosine kinase with
immunoglobulin-like and EGF-like domains (Tie2) monocytes and macrophages are the
primary promoter of tumor angiogenesis (Mantovani et al., 2008; Saavedra, 2001; Sica et
al., 2012; Venneri et al., 2007).
Also, TDFs like M-CSF stimulate macrophage and monocyte migration and
production of EGF, which can activate tumor cell migration (Qian et al., 2009). For
example, unique monocyte/macrophage subpopulations are recruited to extravasating
pulmonary metastatic cells and these populations are required for extravasation as well as
establishment and proliferation of the metastasis (Qian et al., 2009). Furthermore, CCL2
produced by metastatic tumor cells is crucial for this recruitment and CCR2-expressing
monocytes enhance the extravasation of the tumor cells through the production of the
growth factor VEGF-A (Qian et al., 2011).
Cancer and Toll-Like Receptor 4
Many cancer types including gastric, colorectal, liver, pancreatic skin, breast,
head and neck, esophageal, ovarian, cervical, and breast cancer are associated with
elevated concentrations of TLR4 (Mai, Kang, & Pichika, 2013; Thuringer et al., 2011;
Yang, Wang et al., 2014). Additionally, the constitutive expression of some genetic
variants of TLR4 can be linked to cancer (Huang et al., 2014; Stevens et al., 2008; Yang,
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Li, & Feng, 2013). This receptor helps create an environment suitable for continued
cancer cell proliferation and acts to help cancer cells evade immune surveillance (Tang &
Zhu, 2012; Wang, Zhao, et al., 2013). Moreover, the continued activation of TLR4induced inflammatory signaling in chronic inflammatory conditions can contribute to
carcinogenesis (Fukata et al., 2011). Research suggested migration and invasion of
cancer cells could be promoted by TLR4 activating NF-κB under inflammatory
conditions (Ikebe et al., 2009; Kelsh & McKeown-Longo, 2013). Also, TLR4 signaling
activated by LPS promotes cancer cell survival and proliferation in hepatocellular
carcinoma (Wang, Zhu, Huang, Li, & Zhu, 2013). Moreover, a decrease in the cancer
cell’s invasive abilities was observed when TLR4 and NF-κB were inhibited (Earl et al.,
2009).
Furthermore, macrophage and monocyte migration to the tumor site, as well as
tumor cell progression, can be partly attributed to TLR4 activation. In mice with the
TLR4 knock out gene, TAMs were significantly reduced compared to control mice. This
further demonstrated the potential role of TLR4 in macrophage recruitment (Hakim et al.,
2014). In addition, TAMs secreted from the tumor sites in control animals had a higher
expression of TLR4 when compared to TAMS from the knock out mice (Hakim et al.,
2014).
In addition to the role it plays with TAMs, TLR4 might be linked to
chemotherapy resistance (Mallick, Basu, Moorthy, & Ghose, 2017). For example,
Paclitaxel, a chemotherapeutic drug, can directly activate TLR4 and induce a large
inflammatory response and tumor growth in TLR4 positive cells, while this response was
not observed in TLR4 negative cells (Rajput, Volk-Draper, & Ran, 2013). This effect is
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elicited by NF-κB-mediated production of inflammatory cytokines such as IL-6, TNF-α,
IL-1β, Interleukin-8 (IL-8), and VEGF-A, and pro-survival genes such as B-cell
lymphoma-2 (Bcl-2), B-cell lymphoma-extra-large (Bcl-xL), and X-linked inhibitor of
apoptosis protein (XIAP; (Imado et al., 2010; Rajput et al., 2013).
The Gut Microbiome
The human microbiome or microbiota consists of the 10-100 trillion symbiotic
microbial cells harbored by each person (Schwabe & Jobin, 2013). This aggregate
of microorganisms resides on or within any number of human tissues and biofluids
including mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung,
saliva, oral mucosa, conjunctiva, biliary, and gastrointestinal tracts (Butel, 2014; Ursell,
Metcalf, Parfrey, & Knight, 2012). The gastrointestinal tract, also referred to as the gut,
is an organ system that includes the mouth, esophagus, stomach, and intestines (Cheng et
al., 2010). The gut takes in food, digests it to extract and absorb energy and nutrients,
and expels the remaining waste as feces, and it contains the largest number of microbes
(Lozupone et al., 2012; Viaud et al., 2013). The majority of microbes reside in the colon
with approximately 1011 bacteria/gram. Additionally, approximately 99% of these
bacteria are obligate anaerobes (Lozupone et al., 2012; Sender et al., 2016). To date,
research suggested between 300 and 1,000 different species of microbes live in the
gut, with most estimates around 500 species. Interestingly, it is hypothesized 99% of the
bacteria come from about 30 or 40 species with Faecalibacterium. prausnitzii being the
most common species in healthy adults. Additionally, fungi and protists also reside in the
gut but in much smaller concentrations when compared to bacteria; their functions are not
well known (Butel, 2014; Ursell et al., 2012).
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Resident gut microbiota are essential for numerous vital hosts of physiological
processes including digestion of dietary factors, development of the gut immune system,
and colonization resistance against incoming pathogens (Kamada, Seo, Chen, & Núñez,
2013). Bacteria that can reside within the gut are typically separated into two categories:
opportunistic or commensal. Opportunistic bacteria are pathogenic microbes that are
harmful to the human body and can cause illness, inflammation, and disease. Common
strains include E. coli 0157H7, Clostridium difficile, H. pylori, and many others (Butel,
2014; Ursell et al., 2012). Commensal bacteria are non-harmful microbes that can be
symbiotically beneficial (Butel, 2014; Ursell et al., 2012). These strains include but are
not limited to Bifidobacterium, Lactobacilli, Rhumnocauccus, and Faecalibacterium
prausnitzii, and are commonly used as probiotics (Butel, 2014; Ursell et al., 2012).
Commensal bacteria help to not only protect against opportunistic bacteria but they also
help to digest certain polysaccharides and produce beneficial metabolites. Without
bacterial help, mammals are unable to digest and absorb certain carbohydrates such as
certain starches, fiber, oligosaccharides, and sugars (Clarke et al., 2014; Quigley, 2013;
Turnbaugh et al., 2006). For example, healthy rodents raised in a sterile environment and
lacking gut flora consumed 30% more calories just to remain at the same weight as their
normal counterparts (Clarke et al., 2014).
The gut is considered the largest immune organ in the body and the composition
of the gut microbiome plays an important role in the effectiveness of immune function
(Dethlefsen, Huse, Sogin, & Relman, 2008; Dethlefsen & Relman, 2011). Humoral and
cellular immunity develops and matures in humans between infancy and early childhood.
The intestine becomes populated with the microbes during early infancy; however,
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microbiome composition continues to change during the first couple years of life and
stabilizes after two to three years of life at the earliest (Dethlefsen et al., 2008; Dethlefsen
& Relman, 2011). The composition of the microbiome varies greatly in humans across a
lifetime and is highly dependent on many factors including nutrition, climate,
socioeconomic status, family microbiome, the use of antibiotics and other drugs, and
disease state (Dethlefsen et al., 2008; Dethlefsen & Relman, 2011).
A healthy human intestinal tract is always in a state of functional inflammation,
which is considered low-grade inflammation as a result of the constant recognition of
commensal bacteria in the gut (Cario, 2008; Rakoff-Nahoum, Paglino, Eslami-Varzaneh,
Edberg, & Medzhitov, 2004). Microbes residing in the gut contain LPS, peptidoglycan,
and bacterial DNA that are constantly being recognized, thereby activating TLRs and
their respective downstream signaling pathways to induce this low-grade inflammatory
state (Cario, 2008; Rakoff-Nahoum et al., 2004). Consequently, there is cross-talk
between the microbiome and the immune system in normal resting conditions with each
helping to maintain the other (Dethlefsen et al., 2008; Dethlefsen & Relman, 2011;
Murphy et al., 2008). The T helper-17 (TH17) type T-cells can play a role in response to
the intestinal bacteria; however, the commensal bacteria can induce tolerization of the
Th-17 type T-cells. The commensal microbes regulate the expression and release of
immune effector molecules, which are pivotal for maintaining intestinal
homeostasis (Cario, 2008; Strober, 2006). For example, if the contact between
microbiota and intestinal epithelium suddenly increases, the expression of regenerating
islet-derived protein III-gamma (RegIIIγ) increases. This C-type lectin has antimicrobial
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activity and limits bacterial translocation as well as maintains intestinal integrity and
homeostasis (Cario, 2008; Cash, Whitham, Behrendt, & Hooper, 2006; Strober, 2006).
Additionally, immunoglobulin A (IgA), produced by mucosa-associated B-cells,
is another immune effector molecule influenced by the resident microbiota (Cario, 2008;
Cash et al., 2006; Di Giacinto, Marinaro, Sanchez, Strober, & Boirivant, 2005; Strober,
2006). The immune system can recognize many different commensal bacteria and
secrete IgA to help neutralize the bacteria as well as induce inflammation (Barcenilla et
al., 2000; Hamer et al., 2009). However, commensal intestinal microbes can regulate the
expression of IgA, which, in turn, regulate the composition of the intestinal microbiota.
For example, when Bifidobacterium was removed from the intestine, there was a
concomitant increase in the expression of secretory IgA (Wang et al., 2006). Commensal
bacteria’s regulation of immune function is thought to be due in part to the production of
several metabolites including short-chain fatty acids (SCFAs). These metabolites include
acetate, propionate, and butyrate; and regulate the production of cathelicidins, which
exhibit broad-spectrum antibacterial activity against potential pathogens (Müller,
Autenrieth, & Peschel, 2005). Additionally, SFCAs tend to promote a tolerogenic, antiinflammatory cell phenotype crucial for maintaining immune homeostasis, stimulating
tissue repair, and increasing mucus production in the intestines (Barcenilla et al., 2000;
Hamer et al., 2009; Reinshagen, 2015). When peripheral blood mononuclear cells and
neutrophils were exposed to SCFAs, NF-κB was repressed and resulted in the reduced
production cytokine TNF-α (Le Chatelier et al., 2013; Matsumoto et al., 2008).
Furthermore, SCFAs induce activation of G-protein-coupled receptor 109A (GPR109A),
a receptor expressed in high concentration on immune cells including monocytes,
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macrophages, and dendritic cells that respond to both niacin and butyric acid. The
activation of GPR109A reduced the inflammatory response of monocytes in addition to
eliciting Treg cells differentiation (Singh et al., 2014).
Mucositis and Chemotherapy
The intestinal lining consists of a mucous membrane with a single layer of
epithelial cells covered by a layer of mucus. This barrier protects against unnecessary
particles and objects entering the body (Ursell et al., 2012). The mucus layer of the
intestinal epithelium, which is comprised of mucins, trefoil factors, and other
glycoproteins, is important in improving and maintaining membrane integrity and
defense. Mucins, an important component of mucus, are produced by specialized
epithelial cells in the gut called goblet cells (Moncada, Kammanadiminti, & Chadee,
2003). It is believed microbiota play a vital role in the maintenance and production of the
mucosal layer as well as goblet cell development (Kandori, Hirayama, Takeda, & Doi,
1996). Commensal bacteria can increase expression mucus related MUC-2 and MUC-3
genes, resulting in an increase of mucus layer thickness (Barcelo et al., 2000; CaballeroFranco, Keller, De Simone, & Chadee, 2007; Kim, Kim, Whang, Kim, & Oh, 2008;
Mack, Ahrne, Hyde, Wei, & Hollingsworth, 2003). Additionally, butyrate produced by
commensal bacteria is capable of increasing mucus synthesis as well (Hamer et al.,
2008).
When the mucosal barrier is compromised or injured, there is typically mucositis,
which is the painful inflammation and ulceration of the mucous membrane of the
intestinal tract (Bellm, Epstein, Rose-Ped, Martin, & Fuchs, 2000; Lutgens et al., 2005).
Although numbers of conditions are associated with chemotherapy and radiation therapy
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including but not limited to fatigue, loss of appetite, loss of hair, infection, and blistering,
mucositis is one of the most debilitating side effects (Bellm et al., 2000; Lutgens et al.,
2005). Malnutrition, nausea, bloating, vomiting, abdominal pain, diarrhea, and
bacteremia are symptoms associated with mucositis (Bellm et al., 2000; Lutgens et al.,
2005). This condition is frequently associated with reductions in an individual’s ability
to tolerate chemotherapy and can lead to accelerated cancer progression or mortality in
cancer patients (Blijlevens et al., 2000; Sonis et al., 2001; Vera-Llonch et al., 2007).
Bacteria residing in the gut play a role in the metabolism of some
chemotherapeutics and might lead to the formation of toxic metabolites, which plays a
direct role in the development of intestinal mucositis and increased intestinal
permeability (Stringer, Gibson, Bowen, et al., 2009). Intestinal permeability is the term
used to describe the ability of objects to pass from inside the gastrointestinal tract through
the intestinal barrier and into the rest of the body (Bischoff et al., 2014). Chemotherapy
and radiation treatment increase intestinal permeability, which is thought to be at least, in
part, due to villous atrophy (Wang et al., 1996). Some bacteria can increase intestinal
permeability by phosphorylating protein kinase-C phosphorylation via TLR-2 stimulation
(Samonte et al., 2004). Several commensal bacteria, however, improve intestinal
permeability. For example, Bifidobacterium decreases intestinal permeability by
enhancing the expression of zona occludens-1 (ZO-1), a protein that forms tight junctions
(Ewaschuk et al., 2008; Moorthy, Murali, & Devaraj, 2009; Qin et al., 2005).
Additionally, metabolites of bacteria such as short-chain fatty acids are associated with a
reduction in intestinal permeability and an increase in epithelial cell viability
(Venkatraman, Ramakrishna, & Pulimood, 1999; Venkatraman et al., 2003).
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Microbes and Cancer
Although cancer is typically considered to be the result of genetic or
environmental factors, it is believed there is a co-dependent relationship with the
microbiota. This action can vary greatly between individuals and either contribute to or
prevent tumorigenesis by influencing the balance of host cell proliferation and death,
immune system function, hormonal homeostasis, as well as detoxification and
metabolism of host-produced factors, ingested food, and pharmaceuticals (Sears &
Pardoll, 2011; Sheflin et al., 2014). Approximately 20% of human malignancies are
thought to be the result of harmful microorganisms (de Martel et al., 2012); however,
currently only 10 microbes have been designated as carcinogenic to humans. These
oncomicrobes, such as human papillomavirus (HPV), directly trigger a transformation in
the host cell by expressing oncoproteins that integrate oncogenes into the human genome,
promoting tumorigenesis (Sears & Garrett, 2014). On the other hand, bacteria that are
not directly carcinogenic have DNA damaging mechanisms that have evolved to
eliminate competitors in order to survive in the microbial world. When faced with
abnormal conditions or found in unnatural environments, these evolutionary defenses can
lead to mutations in the host that might contribute to carcinogenesis (Putze et al., 2009;
Sears & Garrett, 2014).
When the integrity of the intestinal barrier and/or microbiome is compromised,
the risk of tissue malignancy is increased (Sheflin et al., 2014). Microbiota are adaptive
to their host when abnormal events arise; the selective pressure on the microbiota might
result in translocation to tissues they might not be suited for, which could elicit increased
inflammation and tumorigenesis (Iida et al., 2013; Mantovani et al., 2008; Quigley,
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2013). When intestinal permeability is increased, microbes present at mucosal sites could
not only enter into the body and elicit an immune response but also enter into the tumor
site and become part of the tumor microenvironment (Iida et al., 2013; Vétizou et al.,
2015). Some bacteria might be attracted to the tumor sites because of metabolic products
of the tumor or it might be a more optimal anaerobic environment (Alexander et al.,
2017; Nelson et al., 2015; Sears & Garrett, 2014; Sheflin et al., 2014; Zitvogel, Ayyoub,
Routy, & Kroemer, 2016).
Microbes can then affect cancer growth and proliferation in many ways (Irrazábal,
Belcheva, Girardin, Martin, & Philpott, 2014; Sears & Garrett, 2014) including affecting
genomic stability, proliferative signaling, resistance to cell death, as well as help
metabolize antitumor medications such as chemotherapeutic agents, resulting in tumor
protection (Irrazábal et al., 2014; Sears & Garrett, 2014). Additionally, bacteria can help
modulate the immune effects that elicit proinflammatory responses (Yoshimoto et al.,
2013). Both high and low inflammatory responses can contribute to tumor growth and
survival. Reactive oxygen and nitrogen species, as well as chemokines and cytokines,
can contribute to tumor proliferation and metastasis by activating NF-κΒ, a master
regulator of cancer-associated inflammation (DiDonato, Mercurio, & Karin, 2012).
Chemotherapy and Radiation
Chemotherapy and radiation therapy involve anticancer drugs designed with the
aim to be effective in malignancy treatment; however, these treatments are also generally
toxic for normal cells (Gatti & Zunino, 2005). Numerous side effects are typically
associated with use, some of which are life-threatening. These adverse effects might
require changes in the dosage or in the drug regimen itself to make the treatment tolerable
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to the patient (Gatti & Zunino, 2005). Additionally, drug resistance is another major
issue with anticancer treatments and is recognized as the predominant reason for
chemotherapeutic treatment failure in most human tumors (Gatti & Zunino, 2005). This
has been attributed in part to a large array of genetic factors; however, other aspects such
as drug metabolism, detoxification, or inability to reach the target site are involved
(Gottesman, 2002).
Additionally, microorganisms that reside in the gut might interfere with
chemotherapy therapy. This can be done directly or indirectly and result in three main
clinical outcomes: facilitate drug efficacy, promote anticancer effects, and mediate
toxicity (Alexander et al., 2017). Conversely, it is evident cancer itself and anticancer
therapies affect the microbiota profile in patients. Gut microbiota play a key role in drug
metabolism, both in toxicity and efficacy. For example, the microbiota and immune
system contribute to oxaliplatin’s efficacy (Iida et al., 2013). Gut microbiota prime
myeloid cells for high-level ROS production, causing intratumoral oxidative stress, which
increases oxaliplatin-associated DNA damage and triggers cancer cell death (Iida et al.,
2013). On the other hand, severe diarrhea is a dose-limiting factor with irinotecan and
has been attributed to the ability of the gut microbiota to reactivate the drug locally
(Wallace et al., 2010). For example, in mice, when cyclophosphamide, an alkylating
agent used in hematologic malignancies and solid tumors, was injected, the result was
induced mucosal injury and translocation of bacteria across the intestinal epithelium,
which resulted in gut microbiota-dependent, T helper (TH) cell-mediated antitumor
responses (Viaud et al., 2013). Involvement of the microbiota in response to
chemotherapy was also verified for platinum compounds whose mechanism of action
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relied not only on the formation of platinum-DNA adducts that blocked DNA replication
and stimulated ROS production and oxidative damage but also on their ability to
stimulate immune response (Gui, Lu, Zhang, Xu, & Yang, 2015; Iida et al., 2013).
Pathological disease states or surgical therapies create a condition of dysbiosis
and chemotherapeutics further exacerbate this state, potentially leading to the occurrence
of adverse events (Alexander et al., 2017; Stringer, Gibson, Logan, et al., 2009).
When microbiota were examined after the administration of the chemotherapeutic drug 5
Fluorouracil (5-FU), there was an increase in Clostridium and Staphylococcus species, an
abundance of E. coli, and a decrease in Lactobacillus and Bacteroides species (Stringer,
Gibson, Logan, et al., 2009). During the chemotherapeutic treatment, the number of
bacteria in fecal samples was 100-fold lower than that in healthy control samples,
resulting in a lower diversity of intestinal microbiota (Stringer, Gibson, Logan, et al.,
2009). Bacteroides, Faecalibacterium prausnitzii, and Bifidobacterium species
decreased between 3,000 and 6,000 times normal in samples during the treatment when
compared with healthy control samples. Additionally, the number of pathogenic
Enterococci was significantly higher in individuals undergoing treatment (Stringer,
Gibson, Logan, et al., 2009). Overall, findings suggested the selective killing of
commensal anaerobes following the administration of chemotherapeutics allowed the
expansion of potentially pathogenic microbes (Stringer et al., 2013; van Vliet et al.,
2009).
Probiotics
With it becoming more evident that microbiota play a role in many aspects of
health including disease prevention and the response to anticancer drugs, it is now
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important to maintain or improve the composition of the gut microbiome and prevent or
correct gut dysbiosis. Probiotics, defined as live microorganisms that, when administered
in adequate amounts, confer a health benefit on the host, have been shown to be an
effective tool in this regard (Vyas & Ranganathan, 2012). Typically, probiotics are lactic
acid bacteria, primarily belonging to the genera Lactobacillus and Bifidobacterium; they
have been shown to have beneficial effects in humans (Vyas & Ranganathan, 2012).
Other strains of lactic acid bacteria such as Streptococcus, Bacillus, and Enterococcus are
also used but there is a slight safety concern with Streptococcus and Enterococcus since
some strains of these genera are potentially pathogenic. Saccharomyces yeasts have also
been used as probiotics (Boyle, Robins-Browne, & Tang, 2006; Mego et al., 2013).
Probiotics are thought to be responsible for beneficial health-related effects including
maintenance of the intestinal barrier, production of antimicrobial factors, suppression of
pathogen growth, competition for adhesion and nutrients with potentially harmful
microorganisms, degradation of toxins, regulation of enzymatic activities in the colon,
and activation of the immune response (Gui et al., 2015; Mohajeri et al., 2018; Saavedra,
2001; Serban, 2014).
Studies have reported probiotic bacteria like Lactobacillus have versatile anticarcinogenic properties, which could help reduce or inhibit tumor growth in several
cancers in humans (Abd el-Gawad, el-Sayed, Hafez, el-Zeini, & Saleh, 2004; Singh et al.,
1997). This action is achieved through suppression of the growth of microbes associated
with the production of mutagens and carcinogens, alteration in carcinogen metabolism,
protection of DNA from oxide damage, as well as regulation of immune system (AbedinDo, Taherian-Esfahani, Ghafouri-Fard, & Motevaseli, 2015). Furthermore, probiotics
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have been shown to alter the expression of genes associated with cell death and apoptosis
(Motevaseli et al., 2013), invasion and metastasis (Nouri et al., 2016), cancer stem cell
maintenance (Azam et al., 2014), and cell cycle control (Matsuzaki, Yokokura, & Mutai,
1988). Additionally, Lactococcus lactis can help to induce apoptosis in colon cancers
(Kim, Woo, Kim, Kim, & Lee, 2003). In contrast, Lactobacillus rhamnosus
downregulates the expression of hypoxia-inducible factor (HIF)-1α in breast cancer cell
lines (Esfandiary et al., 2016). Another study suggested a combination of eight Grampositive bacterial strains including Streptococcus thermophilus, Bifidobacterium
longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus,
Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus activated NK
cells and led to suppression of tumor growth and decreased inflammatory cytokine
release (Bui et al., 2015).
Kefir
Kefir is a naturally fermented milk product containing antioxidants and probiotic
bacteria and yeast in addition to providing the protective components of a dairy product.
The lactic acid bacteria and yeast are contained within an exopolysaccharide and protein
complex called a kefir grain. These bacteria and yeast work symbiotically to create the
final product. Kefir traditionally contains significantly less lactose when compared to
milk and regular kefir consumption has also been shown to improve lactose digestion and
tolerance in adults (Hertzler & Clancy, 2003). Although this beverage has been used
extensively in the Middle East, Russia, and Eastern Europe for thousands of years
(Farnworth, 2015), exploration of the health benefits of traditionally produced kefir in
society today is still in its infancy (Ahmed et al., 2013). In addition to the health effects
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derived directly from the bacteria and probiotics, kefir also contains naturally occurring
metabolic by-products of bacteria and yeast fermentation including biologically active
peptides, exopolysaccharides, and organic acids that are also thought to play important
roles in the protective effects and immune system regulation (Garofalo et al., 2015).
Kefir has been explored in many different types of cancer including breast, colon,
gastric skin, and leukemia; however, research has been primarily in vitro and research in
humans is very limited. In a breast cancer cell culture model, six days of kefir exposure
suppressed the proliferation of malignant cells with no effects on the normal tissue (Chen,
Chan, & Kubow, 2007). Additionally, in another study, mice were given kefir prior to
being injected with tumor cells into the mammary glands. The animals then received
kefir from day 4 to day 27 following injections. The results suggested kefir diminished
tumor growth when compared to control (de Moreno de LeBlanc, Matar, Farnworth, &
Perdigon, 2006).
When examining kefir’s effects on cancer, the supernatant of kefir has protective
effects related to preventing DNA damage induced by carcinogens. Since DNA damage
is a crucial part of carcinogenesis, kefir has the potential to reduce the risk of colon
cancer (Grishina et al., 2011). Similarly, a study examining the kefir’s effects on
morphological changes of different types of human melanoma cells induced by
ultraviolet C (UVC) irradiation suggested kefir could protect cells from ultraviolet (UV)
damage after 5 and 24 hours of exposure. It was also hypothesized the effects were
related to active substances other than antioxidant agents (Nagira et al., 2002).
In gastric cancer, kefir induced antiproliferative effects by cell cycle arrest and
early apoptosis of cancer cells (Guo, Al-Sadi, Said, & Ma., 2013). Moreover, kefir had
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effects on proliferation, cell cycle arrest, and apoptosis of two types of human leukemia
cell lines in a dose-dependent manner. Interestingly, kefir’s pro-apoptotic effects were
observed only in the cancerous cells with no negative effects on normal cells (Maalouf et
al., 2011; Rizk et al., 2009).
Altering the gut microbiota is one of the main ways that probiotic-containing food
products like kefir could exert their beneficial effects. This could be done with the
introduction of new species or strains into the gastrointestinal tract or by promoting the
growth of beneficial microbes already present. For example, kefir consumption in an
animal model was shown to increase beneficial microbes such as Lactobacillus and
Bifidobacterium while simultaneously decreasing harmful microbial species such
as Clostridium perfringens (Bourrie, Willing, & Cotter, 2016; Hamet, Medrano, Pérez, &
Abraham, 2016). Moreover, specific strains of Lactobacillus isolated from kefir were
shown to adhere to Caco-2 cells and inhibit the adherence of Salmonella typhimurium
and Escherichia coli O157: H7 (Huang et al., 2013; Santos, San Mauro, Sanchez, Torres,
& Marquina, 2003). In addition, kefir has protective effects against from type II Shiga
toxin produced by E. coli O157: H7 (Kakisu, Abraham, Pérez, & De Antoni, 2007).
Moreover, kefir has been tested against a wide range of pathogenic bacterial and fungal
species and has antimicrobial activity equivalent to common antibiotics and antifungals
including ampicillin, azithromycin, ceftriaxone, amoxicillin, and ketoconazole (Huseini,
Rahimzadeh, Fazeli, Mehrazma, & Salehi, 2012; Rodrigues, Caputo, Carvalho,
Evangelista, & Schneedorf, 2005).
Furthermore, probiotics and kefir can have positive effects on modulating
immune function. Human monocytes responded positively to probiotics; when
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monocytes were exposed to lactic acid bacteria, the result was a higher Interferon-γ (IFNγ) to IL-4 ratio similar to what would be seen during a T-helper (Th1) response (Ai et al.,
2016). It is believed this change might help to reduce autoimmunity and allergic
reactions (Ai et al., 2016). Likewise, mice with non-alcoholic fatty liver disease that
were given kefir for eight weeks showed significantly decreased lipid droplet
accumulation as well as a reduction in the proinflammatory cytokines IL-6, TNF-α, and
IL-1β in the liver tissue (Chen et al., 2016). Interestingly, no published studies have
explored the use of kefir to alter monocyte number and function in a human cancer
survivor model.
Dairy and Cancer
Currently, research is limited in relation to dairy’s role in cancer production or
prevention. However, dairy products elicited positive and negative outcomes in cancer
development situations (Latino-Martel et al., 2016). The positive effects of dairy product
consumption might be due to a variety of dairy components associated with pronounced
effects in various populations with cancer. Consumption of dairy products has played a
role in reducing the risk of colorectal cancer (Lampe, 2011). This risk reduction was
thought to be mainly due to the calcium contained in milk. The risk for colon cancer was
reduced 8% percent and 24% with a dairy-calcium intake of 300 to 900 mg/day,
respectively (Keum, Aune, Greenwood, Ju, & Giovannucci, 2014). It was hypothesized
the reduced cancer risk was due to calcium binding to secondary bile acids and ionized
fatty acids, resulting in reduced proliferative effects in the colorectal epithelium
(Newmark, Wargovich, & Bruce, 1984). Furthermore, calcium might influence multiple
intracellular pathways, leading to differentiation in normal cells and apoptosis in
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transformed cells (Lamprecht & Lipkin, 2001). Consequently, a number of studies
reported reduced cell proliferation in the colon and rectum with the intake of calcium and
dairy products (Holt, Wolper, Moss, Yang, & Lipkin, 2001; Karagas et al., 1998) and
results related to dairy consumption were similar in breast cancer. A moderate intake of
400 to 600 g/day of dairy was associated with a 6% decrease in risk for breast cancer and
a high intake of 600 g/day or higher was associated with a 10% reduction in risk of breast
cancer when compared to a low dairy intake of less than 400 g/day. In addition, it
appeared yogurt and low-fat dairy products were inversely associated with the risk of
developing breast cancer. Although the mechanisms were not clear, it was hypothesized
the calcium and vitamin D found in the dairy products were involved in the risk reduction
in breast cancer (Cauley et al., 2013). There was also limited research on dairy intake
and bladder cancer. Results were inconclusive but suggested a decreased risk for cancer
incidence with high intake of dairy,\ as well as no association with dairy and bladder
cancer (Lampe, 2011; Mao et al., 2011).
Research also suggested dairy product consumption might be associated with an
increased risk for some cancers (Aune et al., 2015; Latino-Martel et al., 2016; Roddam et
al., 2008). High intakes of dairy products, milk (400g/day), low-fat milk(200g/day),
cheese (50g/day), and calcium (400mg/day) were associated with a 3 to 9% increased risk
of prostate cancer (Aune et al., 2015). It was hypothesized an increased concentration of
circulating IGF-1 was the reason for the increased risk; however, this has yet to be fully
elucidated (Roddam et al., 2008). Additionally, lactose consumption might increase the
risk of ovarian cancer; however, research currently available was inconclusive (Cozen et
al., 2002; Cramer, 1989; Goodman et al., 2002). Furthermore, there appeared to be no
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positive or negative association with dairy intake and risk of lung or pancreatic cancer
(Genkinger et al., 2014; Hou, Wu, Gong, & Jiang, 2015; Yu et al., 2016).
When dairy is fermented as present in yogurt or kefir products, the fermentation
process results in a reduction of lactose contained in milk (Keszei, Schouten, Goldbohm,
& van den Brandt, 2010). Fermented dairy products might present a better option for
people concerned about lactose intolerance but would like to incorporate dairy into their
diet. Moreover, fermented dairy products reduce the risk of cancer development (Kato,
Endo, & Yokokura, 1994; Kato, Tanaka, & Yokokura, 1999; Larsson, Andersson,
Johansson, & Wolk, 2008; Lim, Mahendran, Lee, & Bay, 2002). A study of examining
the intake of fermented milk in Swedish men and women indicated a high intake of
cultured milk was correlated with a significantly lower risk of bladder cancer. More
specifically, women and men who consumed two servings of cultured milk per day had a
38% lower risk of bladder cancer than those who never consumed cultured milk (Kato et
al., 1994; Larsson et al., 2008).
Additionally, the fermentation of milk could exert preventive effects on cancer
development due to the bacterial cells of starter cultures or their metabolites (Spanhaak,
Havenaar, & Schaafsma, 1998). Fermented dairy products contain live lactic acid
bacteria; these bacteria and their metabolites modulated the immune response in animals,
suppressed carcinogenesis in rodents (Kato et al., 1994; Kato et al., 1999; Larsson et al.,
2008; Lim et al., 2002), inhibited the activity of enzymes related to carcinogenesis
(Spanhaak et al., 1998), and bound mutagenic and carcinogenic heterocyclic amines in
human gut microbe-associated rodents (Knasmüller et al., 2001).
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Dairy and Monocyte Number and Function
Research is currently limited with respect to dairy and monocyte function.
However, a study examining the effects of diet on monocyte and macrophage function
showed that in healthy individuals, whey protein isolated from milk induced CD68 and
CD11b expression. Both CD68 and CD11b are also considered a pan-myeloid marker,
while CD11b is the integrin alpha M chain; it is important for the adherence of
monocytes to stimulated endothelium (Muller, 2013) as well as plays a role in
phagocytosis of complement coated particles (Le Cabec, Carréno, Moisand, Bordier, &
Maridonneau-Parini, 2002). Additionally, whey protein intake represses IL-6 expression,
which suggests whey helps to polarize monocytes toward the M2-like phenotype. In
addition to an IL-6 decrease, whey protein also decreases TNF-α (Ebaid, Salem, Sayed,
& Metwalli, 2011; Kume, Okazaki, & Sasaki, 2006) and improves concentrations of the
glutathione, which can suppress reactive oxygen species generation in leukocytes
(Bounous, 2000; Lands, Grey, & Smountas, 1999).
Dairy and the Gut Microbiome
As stated earlier, diet plays an important role in the composition and health of the
gut microbiome (Quigley, 2013; Yatsunenko et al., 2012). Milk, cheese, and other dairy
products contain polyunsaturated fats such as conjugated linoleic acid (CLA). Several
health benefits are associated with their consumption (Bassaganya-Riera et al., 2004).
Although the adult microbiome does not have a large number of genes involved in fatty
acid metabolism (Kurokawa et al., 2007), some interactions between polyunsaturated fats
and some probiotics in microbiota have been observed. This could potentially affect the
biological roles of both. Studies in vitro demonstrated some polyunsaturated fats such as
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linoleic, gamma-linolenic, arachidonic, alpha-linolenic and docosahexaenoic acids had
effects on the growth and adhesion of different Lactobacillus strains (Kankaanpää et al.,
2001). Additionally, gut microbes could alter and modify polyunsaturated fat
metabolism to generate an increase of long-chain polyunsaturated fat metabolites that are
able to produce CLA and increase the production of SCFA (Wall et al., 2012). This
action improves immune tolerance, reduces inflammation, improves gut motility, and
optimizes energy metabolism (Gao et al., 2009; Hamer et al., 2008; N. Singh et al.,
2014). Although these findings related to dairy consumption were intriguing, more work
exploring the relationship between consumption of fermented and non-fermented dairy
products and modulation of both the immune system and gut microbiome might be
beneficial in the future.
Exercise and Inflammation
With respect to inflammation, exercise is interesting in that it can both exacerbate
and suppress inflammation. An acute bout of exercise could produce inflammatory
cytokines at concentrations that are up to 100 times greater than at rest (Fischer, 2006;
Louis, Raue, Yang, Jemiolo, & Trappe, 2007). However, this increased cytokine release
enhances lipid and glucose metabolism. Additionally, exercise-induced inflammation
could lead to increased satellite cell activation and improved skeletal muscle recovery
(Beavers, Brinkley, & Nicklas, 2010). Concentrations of inflammatory cytokines elicited
from exercise could reach or even exceed those seen in cases of surgery, trauma, or even
sepsis, and is typically proportional to the intensity of exercise (Henagan et al., 2011;
Pedersen & Hoffman-Goetz, 2000). Although a single bout of exercise might elevate the
concentration of inflammatory biomarkers, chronic exercise could initiate an adaptation
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to the inflammatory stimuli, leading to not only lower resting concentrations of
inflammatory cytokines but also increased ability to attenuate the inflammatory response
after exposure to a stimulus (Petersen & Pedersen, 2005; Ploeger, Takken, de Greef, &
Timmons, 2009; Steensberg et al., 2002). A number of studies showed that chronic
exercise could significantly reduce inflammation and was an important mediator for
reducing inflammation-related diseases (Stewart et al., 2005; Stewart et al., 2007).
Resistance training and endurance training are similar in their ability to reduce
inflammation; however, they act most effectively when combined (Stewart et al., 2007).
Endurance exercise is often recommended as treatment because of its weight loss effects
(Calle & Fernandez, 2010; Henagan et al., 2011). This might be of importance if an
individual has an inability to perform certain types of exercises.
It appears an inverse relationship among inflammatory biomarkers such as IL-6,
TNFα, and CRP and chronic exercise is present in all intensities of exercise and in all
types of individuals (Beavers et al., 2010; Kasapis & Thompson, 2005; Ploeger et al.,
2009). It is important to note some reductions in inflammatory biomarkers might be due
to a loss of adipocytes rather than the exercise intervention directly. This is because
adipocytes are a major producer of many inflammatory cytokines. Adipocyte size
decreases due to increased lipolysis during exercise, resulting in the reduction of body fat
and its capacity to produce these inflammatory markers (Greenberg & Obin, 2006).
Because of this, it is important to separate changes in systemic inflammation related to
exercise training from changes because of a reduction in body fat.
Concentrations of IL-6 increase rapidly with the onset of exercise. Both
monocytes and myocytes are involved in exercise-induced IL-6 production and the
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magnitude of this elevation is correlated with the duration of the exercise event; however,
intensity and type of exercise are also related to the change (Pedersen, 2000). When
comparing running efforts, IL-6 concentrations were four times greater than resting
concentrations after a one-hour bout of exercise. Following a two-and-a-half-hour bout
of exercise, IL-6 increased a minimum of eight times the resting concentration (Fischer,
2006). When resistance-trained and endurance-trained participants were compared, IL-6
concentrations peaked at four times greater than resting after resistance exercise and
endurance training caused a peak 44 times greater than resting concentrations (Louis et
al., 2007).
Unlike other inflammatory biomarkers, TNF-α’s response to acute exercise in
relation to change over time is unique (Louis et al., 2007; Steensberg et al., 2002).
Changes in TNF-α concentrations are often studied after acute exercise bouts due to an
significant increase in plasma one to two hours following exercise rather than during
exercise (Ostrowski et al., 1999; Petersen & Pedersen, 2005). A study examining the
difference between resistance and endurance exercise bouts in individuals trained in each
mode showed TNF-α concentrations were 6.8 times higher than resting pre-exercise
levels when it peaked eight hours following resistance exercise; while endurance training
concentrations were 4.5 times higher and peaked 12 hours following exercise (Beavers et
al., 2010). The effects of chronic exercise training on circulating TNF- α concentrations
have been examined but research was still inconclusive. In a study comparing young and
old trained distance runners, concentrations of TNF-α were significantly different
between the older trained and untrained subjects but no difference was observed in
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younger subjects (Mikkelsen et al., 2013). This study emphasized the potential for
exercise to slow the development of inflammation and the diseases related to it.
Changes in CRP concentrations appear to be dependent on the intensity, duration,
and mode of the activity. A long, single bout of exercise can increase CRP
concentrations, which could then remain elevated for several hours several or days
following exercise (Pedersen, 2000). However, a long-term endurance exercise training
program lowers resting CRP concentrations and the CRP response is attenuated after a
stressful bout of exercise (Prasad, Sung, & Aggarwal, 2012; Stewart et al., 2007).
According to Mikkelsen et al. (2013), chronic inflammation has been associated with
aging; however, chronic endurance exercise over a lifetime resulted in lower CRP
concentrations in older adults compared to those who were not active. This suggested
continued physical activity throughout life might be effective in reducing chronic
inflammation associated with aging (Mikkelsen et al., 2013). Resistance training has the
potential to decrease CRP as well. In overweight women, resistance training showed to
be a viable option to reduce resting CRP concentrations (Phillips et al., 2012). One could
speculate that this decrease might be due to anti-inflammatory adaptation but the
response might also be in part due to loss of adipocytes, which have been shown to
produce CRP in addition to the liver (Bremer & Jialal, 2013).
Monocytes and Exercise
Both the number and phenotype of monocytes can be altered with exercise.
During exercise, mobilized monocytes can enter skeletal muscle and become tissue
macrophages that facilitate repair and regeneration (Peake, Nosaka, & Suzuki, 2005).
This response is most dramatically demonstrated following high-intensity, skeletal
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muscle-damaging exercise (Peake et al., 2005). Additionally, following long bouts of
exercise, delayed monocytosis, or an increase in monocyte numbers, could be observed
for one to two hours but monocyte numbers typically returned to normal within six hours
(Walsh et al., 2011). It also appeared inflammatory monocytes were redeployed more
frequently after exercise (Simpson et al., 2009). An acute anaerobic cycling bout was
performed by healthy males to assess the response of monocytes to an acute anaerobic
exercise (Simpson et al., 2009; Steppich et al., 2000). Results suggested no significant
changes in monocyte numbers with moderate-intensity exercise but high-intensity
exercise elicited an increase in inflammatory monocytes with a two-fold increase in
inflammatory monocytes and a small, 1.3-fold increase in classical monocytes. However,
20 minutes after the exercise was completed, monocyte concentrations returned to
resting, baseline numbers (Simpson et al., 2009; Steppich et al., 2000).
Chronic exercise training decreases monocyte response to stimulus and reduces
inflammatory monocyte number (Phillips et al., 2012; Stewart et al., 2005). In a 12-week
study comparing active and inactive populations and the effects of at least three days per
week of combined endurance and resistance training, exercise reduced inflammatory
monocyte numbers in the inactive group to numbers similar to the active control
(Timmerman, Flynn, Coen, Markofski, & Pence, 2008). Additionally, combined exercise
decreased LPS-induced TNF-α production. Likewise, combined exercise resulted in a
similar response to LPS stimulation between both the active and previously inactive
groups (Timmerman et al., 2008). Some speculated alterations in TLRs might have been
involved. An acute bout of moderate-intensity aerobic cycling could reduce toll-like
receptor expression on monocytes with moderate-intensity exercise (Simpson et al.,
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2009); however, a long bout of intense exercise could induce an acute increase in TLR2
and TLR4 expression on monocytes, which might play a part in a heightened
proinflammatory state (Booth et al., 2010).
Exercise and Microbiome
Sedentary behavior and consumption of a high-fat diet can lead to increased
intestinal permeability and inflammation and changes in microbial composition
(Campbell et al., 2016). However, chronic exercise could induce changes in the
composition of the gut microbiome and positively influence energy homeostasis and
regulation (Bermon et al., 2015; Mika et al., 2015). Exercise could help prevent or
improve these morphological changes; one such way is by reducing cyclooxygenase-2
(COX2) expression in both proximal and distal gut (Campbell et al., 2016). This enzyme
is responsible for the formation of prostanoids including thromboxane and prostaglandins
from arachidonic acid (Fuhrman, 2011). Furthermore, COX-2 is generally not expressed
during normal resting conditions but elevated concentrations of COX-2 are observed in
inflammatory conditions (Kurumbail, Kiefer, & Marnett, 2001).
Additionally, low-intensity exercise can influence the intestinal microbiome by
reducing the transient stool time and, as a result, reduce the contact time between
pathogens and the gastrointestinal mucus layer (Bermon et al., 2015). This evidence
seems to go hand in hand with epidemiological studies that suggested chronic exercise
could have a positive effect on reducing the risk of colon cancer, diverticulosis, and
inflammatory bowel disease (Peters, De Vries, Vanberge-Henegouwen, & Akkermans,
2001). Conversely, it appeared endurance exercise could induce variations in the
gastrointestinal tract due to the reduction of the splanchnic blood flow, which could be as
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high as 80% of basal levels, resulting in toxicity (Peters et al., 2001; Rehrer, Smets,
Reynaert, Goes, & De Meirleir, 2001). Prolonged endurance exercise such as marathons,
triathlons, and ultra-endurance races could increase intestinal inflammation and, as a
result, increase intestinal permeability. This could allow for bacterial translocation from
the colon (Gisolfi, 2000; Peters et al., 2001), resulting in endotoxemia (Brock-Utne et al.,
1988; Camus et al., 1997; Jeukendrup et al., 2000). When concentrations of endotoxins
from gram-negative bacteria in the blood are 5.0 pg/ml or greater, it is considered
endotoxemia. This condition can cause cardiac depression, septic shock, and multiple
organ failure (Danner et al., 1991). To assess the gut’s acute response to endurance
exercise, LPS was measured in marathon runners before, immediately after, and two
hours after the race (Camus et al., 1997; Jeukendrup et al., 2000). Immediately following
the race, increased circulating LPS concentrations were observed; however,
concentrations of LPS were increased even further one hour following the race with 68%
of individuals with LPS concentrations between 5.0 pg/ml and 15.0 pg/mL (Camus et al.,
1997; Jeukendrup et al., 2000). Additionally, randomly selected exhausted ultramarathon runners requiring medical treatment were randomly selected to undergo LPS
assessment; endotoxemia was observed in 81% of the selected individuals and 2% had
lethal levels above 1 ng/mL (1000pg/ml; Brock-Utne et al., 1988).
It is believed elevated concentrations of circulating LPS might be one reason
TLR4 expression is upregulated on monocytes during long bouts of exercise(Marycz et
al., 2016); however, research was inconclusive. When cells were incubated with the
TLR4 ligand LPS, TLR4 was upregulated on monocytes when compared to the control
(Devaraj et al., 2008). Conversely, a low dose of 0.4ng/kg of LPS did not increase TLR-
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4 expression (Devaraj et al., 2008; Lichte et al., 2013). Clearly, the link between TLR4,
LPS, and gut health remains to be fully explored.

51

CHAPTER III
METHODS
Participants
Male and female participants 40 years of age and older were recruited from the
University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI). Participant
recruitment strategies involved verbal communication from the staff at the UNCCRI. To
be eligible for this study, participants were currently enrolled in the UNCCRI program,
undergoing chemotherapy or radiation treatment, or had undergone chemotherapy or
radiation treatment within two years prior to starting the study. Participants were not
ingesting probiotic foods or supplements or were willing to stop ingesting these
probiotics at least one month prior to starting this study. Additional inclusion criteria
consisted of the following:
•

Age: 40-80 years

•

Sex: Female or male

•

Cancer survivor: Phase 1 or phase 2 in the UNCCRI program

•

Medications: Currently undergoing chemotherapy treatment or lower body
radiation, or have undergone chemotherapy treatment or lower body
radiation within the last month prior to starting the study

•

Informed consent: The capability and willingness to give written informed
consent, to understand the exclusion criteria, and to accept that the
randomized group assignment is required,
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Exclusion criteria consisted of the following:
•

Allergy to milk or any beverage: Individuals with a known milk allergy or
any of the listed ingredients

•

Probiotics: Individuals ingesting probiotic supplements or foods containing
probiotic who are not willing to stop supplementing with them

•

Significant CVD or disorders: Including but not limited to serious
arrhythmias, cardiomyopathy, congestive heart failure, stroke or transient
ischemic attacks, peripheral vascular disease with intermittent claudication,
acute, chronic or recurrent thrombophlebitis or myocardial infarction

•

Pregnancy: Individuals who are pregnant

•

Diabetes: Fasting glucose > 125 mg/DL or two-hour glucose of > 200
mg/dL during oral glucose tolerance test

•

Blood pressure: Systolic blood pressure > 160mmHg and diastolic blood
pressure > 100mmHg.
Informed Consent and Blood Draw

This project was approved by the University of Northern Colorado’s Institutional
Review Board (IRB; see Appendix A). During initial recruitment visit, participants were
asked to review and sign an informed consent form approved by the IRB (see Appendix
B). A copy of the informed consent was be provided to the participant to keep as a
reference. Additionally, the participants were asked to complete a three-day dietary log
(see Appendix C) and assigned in a non-random balanced manner to either the Kefir
(KEF) group or control (CON) group based on tolerance of kefir.
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Blood was obtained between the hours of 7 am and 10 am from participants for
analysis both prior to starting and after completing the study. Prior to blood draws, the
participants were asked to complete a 24-hour dietary log and to refrain from structured
exercise for a minimum of 72 hours and fast for 12 hours (nothing to eat or drink except
water) prior to the visit. A trained phlebotomist performed venipuncture on a prominent
vein in the forearm and the collected blood was separated into whole blood, plasma, and
serum. Following blood collection, all participants were asked to follow the structured
exercise regimen as led by the staff at UNCCRI. A generalized view of the study design
is presented in Figure 1.
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Figure 1. Study design overview.
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Pre-Intervention and Post-Intervention Measures
Descriptive data were obtained from each client prior to starting the study and
after the intervention was concluded. Descriptive data included age, height, weight, sex,
ethnicity, body composition, cancer type, cancer stage, cancer treatment history, current
medications, measures of emotional and psychological health, dairy consumption, and
fermented food consumption. During the intervention period, all participants completed
a survey designed to evaluate gastric distress (see Appendix D).
Height was measured using a stadiometer (BSM170, Cerritos, CA). Body weight
was measured using an InBody scale (InBody Scale, Cerritos, CA scale). Body
composition was obtained using an eight-point tactile electrode system (InBody 770,
Cerritos, CA; McLester, Nickerson, Kliszczewicz, & McLester, 2018), the three-site
skinfold technique, and the waist to hip circumference measurement; all body
composition techniques were performed on the same day to reduce variation. Aerobic
fitness was measured as VO2peak using the UNCCRI treadmill protocol for VO2peak.
This protocol involved gradual speed and grade adjustments at each stage until volitional
fatigue. The VO2peak was then calculated based on the speed and grade at protocol
completion (Shackelford, Brown, Peterson, S Shaffer, & Hayward, 2017). An estimated
one-repetition maximum (1RM) was used to assess muscular strength. Muscular strength
was evaluated for lat-pull down, seated row, chest press, shoulder press, leg extension,
leg curls, and leg press exercises. Briefly, all subjects completed the strength exercises to
failure, which must occur between 3-10 repetitions. If the participant was able to
complete more than 10 repetitions, they were asked to rest for two minutes and repeat the
exercise at a greater weight until failure occurred between 3-10 reps. The 1RM for each
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exercise was evaluated using the Bryzcki 1RM equation, which estimated 1RM to failure
occurred between 3-10 repetitions (Brzycki, 1993).
To assess emotional and psychological health, participants were asked to
complete the Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh,
1961; Eskelinen & Ollonen, 2011; Wang & Gorenstein, 2013), Revised Piper Fatigue
Scale (Piper et al., 1998), and Quality of Life Index III (Rustoen, Moum, Wiklund, &
Hanestad, 1999) prior to starting and after completing the 12-week intervention (see
Appendices E, F, and G, respectively). Finally, participants were given a dairy
consumption questionnaire (Wiley, 2011; see Appendix H) and a fermented foods
questionnaire (see Appendix I) to evaluate their intake of dairy products and fermented
foods (Chaiyasut, Sivamaruthi, Markhamrueang, Peerajan, & Kesika, 2017), respectively.
Exercise Program
All participants followed the structured exercise regimen established by their
trainer three times per week. Each exercise session was 60 minutes in duration and was
split into three sections: 20 minutes of aerobic training, 30 minutes of resistance training,
and 10 minutes of stretching and flexibility. Aerobic training could include but was not
limited to outdoor walking, cycling, treadmill, and arm ergometer. Resistance training
consisted of targeting the following four major muscle groups while incorporating
balance into the exercises: chest, back, lower body, and core. Each resistance exercise
was performed for three sets of 10 repetitions each. Although all participants followed
the same session structure, the intensity of exercises varied depending upon the phase in
which they were enrolled (Brown, Shackelford, Hipp, & Hayward, 2019).
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Dietary Intervention
Participants were assigned in non-random balanced manner to either the KEF or
CON group. The KEF group was asked to ingest 8 oz. of lactose-free, low-fat kefir
(Lifeway Foods, Inc. Morton Grove, IL) after each exercise regimen for the 12 weeks.
The kefir consumed by the participants contained 12 different strains of probiotics and
15-20 billion colony forming units (CFU) per 8 oz. serving. Other nutritional
information included calories (140), carbohydrates (20g), added sugars (8g), protein
(11g), saturated fat (1.5g), unsaturated fat (0.6g), Vitamin A (90mcg), Vitamin D (5mcg),
calcium (390mg), and potassium (376mg). The strains of probiotics were as follows:
Lactobacillus. Lactis, Lactobacillus. rhamnosus, Streptococcus. diacetylactis,
Lactobacillus. plantarum, Lactobacillus. casei, Saccharomyces. florentinus, Leuconostoc.
cremoris, Bifidobacterium. longum, Bifidobacterium. breve, Lactobacillus. acidophilus,
Bifidobacterium. lactis, and Lactobacillus. reuteri. The participants were asked to ingest
the kefir within 30 minutes following each structured exercise bout. The kefir was
consumed in the presence of a person on the research team or a member of the UNCCRI
staff. The CON group was not given anything to ingest post-exercise for the 12 weeks
and asked to continue their normal post-exercise routine. All participants were asked to
continue their usual post-exercise dietary habits.
Assessments During the Intervention
Participants were given a gastric distress survey (see Appendix D) weekly over
the course of the 12-week intervention to assess gastric distress including the urge to
defecate, nausea, reflux, stomach fullness, abdominal cramps, and gas or flatulence
(Stuempfle & Hoffman, 2015).
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Dietary Assessment
All participants completed three different written paper and pencil dietary surveys
prior to starting and after completing the intervention (see Appendices D, H, and I). A
three-day dietary log (see Appendix C) and post-exercise dietary questionnaire were
completed in the first week and the final week of the study. They were used to ensure
there were no major dietary changes from the start of the study. Additionally, a 24-hour
dietary log was completed prior to each blood draw to ensure there were no changes in
dietary patterns such as fasting (no food or drink except water) 12 hours prior to the
blood draw.
Inflammatory Biomarkers
An assessment of inflammatory status at rest was obtained using the circulating
(serum or plasma) biomarkers, IL-6 (Abcam Biotechnology company, Cambridge, MA)
and CRP (Alpco, Salem, NH). An enzyme-linked immunosorbent assay (ELISA) for
each respective biomarker was used with a plate reader (BioTek, Winooski, VT).
Biomarker of Gut Dysbiosis
Lipopolysaccharide (LPS) concentrations were measured in the plasma as a
biomarker of gut dysbiosis. Lipopolysaccharide was analyzed using an ELISA (LifeSpan
Biosciences, Seattle, WA) with a plate reader (BioTek, Winooski, VT).
Monocyte Function Measures
Monocyte function was measured by preparing Roswell Park Memorial Institute
(RPMI) cell culture media (Sigma Aldrich, St. Louis, MO) with L-glutamine,
streptomycin, and penicillin (Sigma Aldrich, St. Louis, MO) in a dilution of 1:100,
respectively. Blood samples were then prepared in a 1:10 dilution in the prepared cell
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culture media, plated in 2 mL volumes, and treated with 50 μL of 1 mg/1 mL LPS (S.
enteriditis; Sigma Aldrich, St. Louis, MO), resulting in a final concentration of 25 μL of
LPS per 1 mL of prepared sample. Control wells were treated with 50 μL of media.
After 24 hours of incubation at 37°C and 5% CO2, plates were centrifuged for eight
minutes at 800 rcf. Serum supernatants were harvested, aliquoted, and stored at -80°C
until analysis. Supernatants were analyzed for the inflammatory markers IL-6 and TNF-α
using an ELISA (Ray Biotech, Peachtree Corners, GA) and plate reader (BioTek,
Winooski, VT).
Monocyte Phenotypes
Upon completion of blood collection, individual samples were prepared in
duplicate for flow cytometry analysis. Whole blood samples from sodium-heparintreated blood collection tubes (Beckton Dickinson, East Rutherford, NJ) were incubated
with fluorescent-labeled antibodies for the CD14 (anti-human CD14-FITC, MEM18) and
CD16 (anti-human CD16-PE, MEM154; eBioscience, San Diego, CA). Matching
isotype control samples were also prepared (mouse IgG1 iso control-FITC and mouse
IgG1 iso control-PE; eBioscience, San Diego, CA). Samples were run on an Attune NXT
flow cytometer (Thermo Fisher Scientific, Waltham, MA) utilizing a 488nm argon-ion
laser configured for FITC and PE with log amplification and analyzed with FCS Express
6 Flow Cytometry Software (De Novo Software, Glendale, CA). Gates were set to
analyze monocytes in each sample. Both counts (numbers) and total percentage of
immune cells were provided for total monocytes and percentages of monocytes were
provided for CD14+CD16-, CD14+CD16++, and CD14++CD16+ phenotypes.
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Statistical Analysis
A previous study evaluating CRP concentrations in older adults before and after a
combined aerobic and resistance training program resulted in a 58% decrease in serum
CRP concentrations following 12 weeks of exercise intervention (Stewart et al., 2007).
This difference translated to a sample size of at least six people per KEF or CON group
for 80% power (alpha = 0.05). The SPSS statistical software (IBM Corporation,
Armonk, NY) was used perform analysis of descriptive measures including age, height,
weight, sex, ethnicity, body composition, muscular strength, cardiovascular fitness,
cancer type, cancer stage, cancer treatment history, current medications, and
psychological health. Data are presented as mean and standard deviation. A mixedmeasures, repeated measure (group; kefir vs. control) (time; pre vs. post) analysis of
variance (ANOVA) was performed with independent variables consisting of treatment
groups and time and the dependent variables including biomarkers of inflammation,
biomarkers of gut dysbiosis, and monocyte phenotype. Pearson’s correlations were run
to assess relationships among the following: body size and composition, biomarkers of
inflammation, biomarkers of gut dysbiosis, dietary habits, and monocyte phenotype. The
α level of significance was defined as p < .05.
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CHAPTER IV
RESULTS
Participant Characteristics
All participants were recruited at UNCCRI; of those contacted, 40 individuals met
the qualifications to participate, 17 declined to participate, five expressed interest but
declined, and three started the study but dropped out. Those who dropped out reported
reasons related to side effects of cancer treatments and barriers related to scheduling.
Participants (N = 19) consisted of males (n = 7) and females (n = 12) whose age ranged
from 42- to 78-years-old with an average age of 61.5 ± 10.5 years of age. Ethnicities for
all participants were Caucasian (n = 17) and Hispanic (n = 2); with both groups
combined, the average time participants had been trained at UNCCRI before the
intervention was 5.9 ± 5.6 months.
Participant cancers consisted of varying types and stages. Cancer types and
stages consisted of breast ([n = 3; stage 0 (n = 1) and stage 2 (n = 2]), prostate ([n=3;
Gleason scale stage 7 (n = 1), stage 8 (n = 1), and stage 9 (n = 1]), and endometrial (n =
1, stage 3). Cancer types and stages for CON included breast ([n=7; stage 1 (n = 3), stage
2 (n = 2), and stage 3 (n = 2]), renal (n = 1, stage 3), ovarian (n = 1, stage 2), and
leukemia (n = 1, stage 2). Treatments for both groups combined (N = 19) included
chemotherapy (n = 13), radiation (n = 5), or a combination of both (n = 2). Treatments
for KEF included chemotherapy ([n = 5; Carboplatin (n = 2), Doxorubicin (n = 2),
Paclitaxel (n = 2), Irinotecan (n = 1), Docetaxel anhydrous (n = 1), and Folfox (n = 1]),
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radiation therapy ([n = 3; external beam radiation (n = 4) and internal radiation (n = 1]),
and one participant underwent Carboplatin, Paclitaxel, and external beam radiation.
Cancer treatments for CON included chemotherapy ([n = 7); Docetaxel anhydrous (n =
4), Cyclophosphamide (n = 4) Paclitaxel (n = 3), Doxorubicin (n = 2), Carboplatin (n =
2), Dasatinib (n = 1), Pertuzumab (n = 1), and Trastuzumab (n = 1]) or radiation therapy
([n = 2; external beam radiation (n = 1) and internal beam radiation (n = 1]), and one
participant underwent Adriamycin, Cyclophosphamide, Paclitaxel, and external beam
radiation.
At the pre-intervention time point, time since treatment for all participants ranged
from zero months (currently in treatment) to 18 months since treatment with an average
of 7.1 ± 6.2 months. Time since treatment for KEF ranged from zero months (currently
in treatment) to 15 months and CON ranged from zero months (currently in treatment) to
18 months. No significant time since treatment differences were found between groups at
the pre-intervention time point (see Table 1).
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Table 1
Participant Characteristics
KEF
(n = 9)

CON
(n = 10)

Age (yrs.)

59.2 ± 10.5

63.6 ± 10.7

Males (n)

5

2

Females (n)

4

8

Time Since Treatment months)

7.7± 6.2

6.9 ± 6.5

Chemotherapy (n)

5

7

Radiation (n)

3

2

Chemotherapy & Radiation
1
1
Combined (n)
Note. Values expressed as mean ± standard deviation. There were no significant
differences between groups. KEF (Kefir intervention group), CON (Control group).

Body Size and Composition
Both groups were similar with respect to pre-intervention height, weight, and
body fat percent (see Table 2). Average height for all participants ranged from 150 to
180.3 centimeters with an average of 165.6 ± 7.4 centimeters. With both KEF and CON
groups combined, body weight averaged 76.0 ± 19.1 kg at the pre-intervention time point
and 76.2 ± 19 kg at the post-intervention time point. No significant main effects or
interactions were observed (see Table 2).
For all participants, when KEF and CON groups were combined, pre-intervention
body fat percent ranged from 23.9 to 51.8% with an average of 36.4 ± 8.1%; postintervention body fat percent for all participants, when KEF and CON groups were
combined, ranged from 21.8 to 45% with an average of 34.6 ± 8.2%. A time by group
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interaction was observed where KEF-POST body fat percent was 10.7% lower than KEFPRE body fat percent (p = .019). Furthermore, when KEF and CON groups were
combined at the pre-intervention time point, lean body mass ranged from 37.0 to 56.8 kg
with an average of 46.4 ± 8.2 kg. At the post-intervention time point when KEF and
CON groups were combined, lean body mass ranged from 39.2 to 71.9 kg with an
average of 48.5 ± 8.9 kg. There was a significant main effect for time where preintervention lean body mass was 4.4% lower than post-intervention (p = .002).
Furthermore, there was a significant time by group interaction where KEF-PRE lean
body was 8.4% lower than KEF-POST (p = 0.014; see Table 2).

Table 2
Body Size and Composition
KEF-PRE

KEF-POST

CON-PRE

CON-POST

Height (cm)

165.1 ± 7.9

165.1 ± 7.9

165.6 ± 6.9

165.6 ± 6.9

Weight (kg)

80.1 ± 20.5

79.5 ± 19.6

74.1 ± 18.6

72.4 ± 19.0

Body fat (%)

37.1 ± 8.32

33.3 ± 9.09γ

35.9 ± 8.39

35.7 ± 7.6

Lean Body
103.3 ± 21.6 111.9 ± 23.4*γ 101.9 ± 15.8
102.9 ± 16.4*
Mass (kg)
Note. Values expressed as mean ± standard deviation. * indicates a time effect where lean
body mass pre-intervention values are lower than post-intervention (p = .002). γ indicates
a time by group interaction, where KEF-PRE body fat percent is higher than KEF-POST
(p = .019), and KEF-PRE lean body mass is lower than KEF-POST (p = .014). KEF-PRE
(Kefir group pre-intervention), KEF-POST (Kefir group post-intervention), CON-PRE
(Control group pre-intervention), CON-POST (Control group post-intervention).
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Aerobic Fitness and Muscular Strength
When KEF and CON groups were combined, all participants had VO2peaks that
ranged from 7.5 to 34.6 ml/kg/min and averaged 23.6 ± 8.0 ml/kg/min (see Table 3) at
the pre-intervention time point. There was a significant time effect (p = .001). When
KEF and CON groups were combined, pre-intervention VO2peak values were 8.4%
lower than post-intervention values.

Table 3
Aerobic Fitness and Muscular Strength
KEF PRE
(n = 9)

KEF-POST
(n = 9)

CON-PRE
(n = 10)

CON-POST
(n = 10)

VO2Peak
(ml/kg/min)

25.1 ± 7.6

27.2 ± 7.7*

22.2 ± 8.5

24.0 ± 7.5*

Chest Press (kg)

49.5 ± 29.2

57.7 ± 6.0*

42.7 ± 28.6

48.0 ± 29.5*

Lat Pulldown (kg)

56.2 ± 21.6

58.1 ± 21.3*

38.7 ± 22.6

45.9 ± 21.9*

Leg Press (kg)

118.0 ± 40.6

137.2 ± 40.0*

95.7 ± 47.3

104.0 ± 49.4*

Chest Strength/kg
Body Weight

0.59 ± 0.2

0.65 ± 0.2

0.48 ± 0.3

0.59 ± 0.5

0.70 ± 0.2

0.76 ± 0.2

0.52 ± 0.2

0.63 ± 0.2

Leg Strength/kg
Body Weight

Leg Strength/kg
1.4 ± 0.3
1.7 ± 0.3
1.2 ± 0.5
1.3 ± 0.4
Body Weight
Note. Values expressed as mean± standard deviation. * indicates a time effect for where
pre-intervention values are lower than post-intervention values (VO2peak; p < .001, chest
strength; p = .027, lat strength; p < .001, leg strength; p = .015). KEF-PRE (Kefir group
pre-intervention), KEF-POST (Kefir group post-intervention), CON-PRE (Control group
pre-intervention), CON-POST (Control group post-intervention).
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A significant main effect for time, but no time by group interaction, was observed
for absolute chest press strength, lat pulldown strength, and leg press strength. Average
chest press strength at the pre-intervention time point for both KEF and CON groups
combined ranged from 14.85 to 114.31 kg with an average of 46.15 ± 28.21 kg and
improved an average of 14.08% at the post-intervention time point (p = .027). Lat
pulldown strength for all participants at the beginning of the study ranged from 18.7 to
94.03 kg, averaged 47.5 ± 23.2 kg, and increased an average of 11.5% at the postintervention time point (p < .001). Leg press strength for all participants ranged from
52.7 to 205.7 kg with an average of 106.3 ± 44.5 kg at the pre-intervention time point and
increased an average of 12.7% at the post-intervention time point (p =.015). Some
notable correlations at the pre-intervention time point were observed when KEF and
CON groups were combined: significant positive correlations between body weight and
chest press strength (r = 0.635, N = 19, p = .0035), body weight and lat pulldown strength
(r = 0.535, N = 19, p = .036), and body weight and leg press strength (r = 0.483, N = 19,
p = .036). Additionally, an overall strength difference was observed between sexes at
both time pre-intervention and post-intervention time points including chest strength (p =
.0047, p = 0.031) and leg strength (p = .017, p = .0256). These sex differences did not
persist within either KEF or CON.
Psychological Measures
The Beck Depression Inventory (BDI, Beck et al., 1961) scores for all participants
averaged 7.2 ± 5.3 at the pre-intervention time point and 4.6 ± 3.4 post-intervention time
point (see Figure 2) and there was a significant main effect for time where preintervention scores were 37.9% higher than post-intervention scores (p =.008). Piper
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Fatigue Scale (Piper et al., (1998) scores for all participants ranged from 0.02 to 7.7 with
an average of 4.0 ± 2.1 at the pre-intervention time point and from 0 to 6.18 with an
average of 3.1 ± 2.1 at the post-intervention time point. (see Figure 3). There was a
significant main effect for time where pre-intervention scores were 22.3% higher than
post-intervention scores (p = .002). There was also a significant time by group
interaction where KEF-PRE scores were 40.9% higher than KEF-POST (p = .002). The
Quality of Life Index (QOL, Rustoen et al., 1999) score for all participants averaged 22.5
± 3.5 at the pre-intervention time point and 23.3 ± 3.2 at the post-intervention time point
(see Figure 4). No significant main effects or interactions were found with respect to
QOL scores.
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Figure 2. Beck Depression Inventory scores. Values expressed as mean ± standard
deviation. * indicates a main effect for time (p = .08) where pre-intervention was higher
than post-intervention. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir
group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).
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Figure 3. Piper Fatigue Scale scores. Values expressed as mean ± standard deviation.
* indicates a main effect for time (p = .002) where pre-intervention was higher than postintervention. γ indicates time by group interaction (p = .002) where KEF-PRE was
higher than KEF-POST. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir
group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).
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Figure 4. Quality of Life Index score. Values expressed as mean ± standard deviation.
There were no significant main effects or interactions. KEF-PRE (Kefir group preintervention), KEF-POST (Kefir group post-intervention), CON-PRE (Control group preintervention), CON-POST (Control group post-intervention).

Dairy Consumption
At the pre-intervention time point, participants in KEF and CON groups
combined consumed some form of dairy ranging from zero to seven days per week with
an average of 4.05 ± 2.01 days of dairy consumption per week. A significant group
effect was observed at the pre-intervention time point (p = .008) with KEF consuming
dairy 57% more frequently than CON. Dairy consumption in KEF ranged from three to
seven days per week with an average of 5.4 ± 1.4 days per week and CON dairy
consumption ranged from zero to five days per week with an average of 3.1 ± 1.9 days
per week. The most common dairy items consumed included cheese (KEF, n = 7; CON,
n = 7), yogurt (KEF, n = 6; CON, n = 6), milk for breakfast cereal (KEF, n = 4; CON, n
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= 3), and milk for coffee (KEF, n = 4; CON, n = 2). If a participant was consuming dairy
that contained probiotics, he/she was asked to cease consuming the food prior to the start
of intervention. One notable correlation with dairy consumption was observed at the preintervention time point. When KEF and CON groups were combined, there was a
significant positive correlation between dairy consumption frequency and body weight (r
=0.606, N = 19, p = .006).
Fermented Food
At the pre-intervention time point, the number of different fermented foods
consumed by all participants ranged from zero to five types of fermented foods with an
average of 1.9 ± 1.2 different food types. The number of different types of fermented
food consumed by KEF ranged from one to three different foods with an average of 1.9 ±
0.8, while CON ranged from zero to five different types of fermented food with average
of 2 ± 1.8 different types. When taking into consideration those who reported consuming
fermented foods from both KEF and CON groups, the frequency of consumption ranged
from two times per month to every day with an average of 3.9 ± 2.7 times per week.
Frequency of fermented food consumption for KEF ranged from two times per month to
every day with an average of 4.4 ± 3 days per week. The CON fermented food
consumption ranged from one day per week to every day with the average of 3.4 ± 2.4
times per week. The most commonly consumed fermented foods included yogurt (KEF:
n = 6, 4.3 days/week; CON: n = 6, 3.3 days/week), pickles (KEF: n = 4, 1.5 days/week;
CON: n = 1, four days/week), and wine/beer (KEF: n = 2, two days/month; CON: n = 3,
two days/month). If a participant was consuming fermented foods that contained
probiotics, he/she was asked to cease consuming the food prior to the start of
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intervention. While there were no main effects or interactions with respect to any of the
measures of fermented food consumption, there was a notable positive correlation. At
the pre-intervention time point with KEF and CON groups combined, there was a
significant correlation between fermented food consumption frequency and body fat (r
=0.616, N = 19, p = .019).
Gastric Distress
Pre-intervention gastric (GI) distress scores for both KEF and CON groups
combined ranged from 0 to 31 with an average of 10.9 ± 8.6; post-intervention GI
distress scores ranged from 0 to 22 with an average of 6.3 ± 7.6 (see Figure 5). There
was a significant main effect for time (p = .013) with 42.7% lower GI distress scores at
the post-intervention time point when both KEF and CON groups were combined. There
was also a significant time by group interaction (p = .021) with KEF-POST scores
averaging 64.7% lower than KEF-PRE scores. Furthermore, a notable significant inverse
correlation was observed between GI distress and fermented food consumption frequency
(r = -0.560, N = 19, p = .037) at the pre-intervention time point when KEF and CON
groups were combined.
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Figure 5. Gastric distress scores. Values expressed as mean ± standard deviation.
* indicates a main effect for time (p = .013) where pre-intervention was higher than postintervention, γ indicates a time by group interaction (p = .021) where KEF-PRE was
higher than KEF-POST. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir
group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).

Serum Interleukin-6
Fasted and rested serum interleukin (IL-6) concentrations, when KEF and CON
groups were combined at the pre-intervention time point, ranged from 0.5 to 11.34 pg/ml
with an average of 4.03 ± 2.35 pg/ml. Post-intervention IL-6 concentrations ranged from
2.04 to 14.59 pg/ml with an average of 4.18 ± 2.96 pg/ml (see Figure 6). No main effects
or group interactions were observed. However, at the pre-intervention time point, there
was a notable, significant inverse correlation between dairy consumption frequency and
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serum IL-6 concentrations (R =-0.506, N = 19, p = .032) when KEF and CON groups
were combined.
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Figure 6. Serum interleukin 6 concentrations. Values expressed as mean ± standard
deviation. There were no significant main effects or interactions. KEF-PRE (Kefir group
pre-intervention), KEF-POST (Kefir group post-intervention), CON-PRE (Control group
pre-intervention), CON-POST (Control group post-intervention).

Serum C-Reactive-Protein
Resting serum C-reactive-protein (CRP), when both KEF and CON groups were
combined at the pre-intervention time point, ranged from 0.77 to 15.25 mg/L with an
average of 4.47 ± 4.43 mg/L. At the post-intervention time point, CRP ranged from 0.52
to 12.87 mg/L with an average of 3.56 ± 3.87 mg/L (see Figure 7). No significant main
effects or interactions were observed. At the pre-intervention time point, there was a
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notable significant positive correlation between CRP and body fat percent (r = 0.46, N =
19, p = .0475) when both KEF and CON groups were combined.

10

(m g /L )

C R P C o n c e n t r a t io n

15

5

T
S

E

O

R

P

P
C

O

N

N
O
C

F
E
K

K

E

F

P

P

O

R

S

E

T

0

Figure 7. Serum C-reactive protein concentrations. Values expressed as mean ±
standard deviation. There were no significant main effects or interactions. KEF-PRE
(Kefir group pre-intervention), KEF-POST (Kefir group post-intervention), CON-PRE
(Control group pre-intervention), CON-POST (Control group post-intervention).

Serum Lipopolysaccharide Concentrations
Serum lipopolysaccharide (LPS) concentrations, when both KEF and CON groups
were combined at the pre-intervention time point, ranged from 0 to 103.46 pg/ml with an
average of 33.27 ± 33.45 pg/ml. At the post-intervention time point when both KEF and
CON groups were combined ranged from 0 to 99.86 pg/ml with an average of 24.4 ±
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27.43 pg/ml. (see Figure 8). There was a significant group by time interaction with KEF-
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Figure 8. Serum lipopolysaccharide concentrations. Values expressed as mean ±
standard deviation. * indicates a time by group interaction (p = .0137) where KEF-PRE
was higher than KEF-POST. KEF-PRE (Kefir group pre-intervention), KEF-POST
(Kefir group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).

Stimulated Interleukin-6 Production
Whole blood LPS stimulated IL-6 production, defined as the difference between
stimulated and unstimulated IL-6 concentrations, for both KEF and CON groups
combined at the pre-intervention time point ranged from 1.68 to 9.9 ng/ml and averaged
4.92 ± 2.33 ng/ml. At the post-intervention time point, both KEF and CON groups
combined ranged from 0.79 to 12.96 ng/ml with an average of 4.98 ± 3.21 ng/ml. (see
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Figure 9). A time by group interaction was observed with stimulated IL-6 production in
KEF-POST 17.8% lower than KEF-PRE (p = .034).
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Figure 9. Stimulated interleukin-6 production. Values expressed as mean ± standard
deviation. * indicates a time by group interaction (p = .034) were KEF-PRE was higher
than KEF-POST. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir group
post-intervention), CON-PRE (Control group pre-intervention), CON-POST (Control
group post-intervention).

With both groups combined, IL-6 production per monocyte ranged from 17.41 to
99.43 fg/monocyte with an average of 44.81 ± 23.61fg/monocyte at the pre-intervention
time point and from 2.3 to 77.60 fg/monocyte with an average of 28.61 ± 20.57
fg/monocyte. A significant main effect for time (p = .019) was observed where preintervention IL-6 production per monocyte was 36.2% higher than post-intervention IL-6
production per monocyte (p = .019; see Figure 10).
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Figure 10. Stimulated interleukin-6 production per monocyte. Values expressed as mean
± standard deviation. * indicates a main effect for time (p = .019) where pre-intervention
was higher than post-intervention. KEF-PRE (Kefir group pre-intervention), KEF-POST
(Kefir group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).

Stimulated Tumor Necrosis Factor-α
Whole blood LPS stimulated production of tumor necrosis factor-α (TNF-α),
defined as the difference between stimulated and unstimulated TNF-α concentrations
when both KEF and CON groups were combined, averaged 4.40 ± 3.73 pg/ml at the preintervention time point and 3.62 ±2.67 ng/ml at the post-intervention time point (see
Figure 11). There was a significant main effect for time where pre-intervention
production was 25.1% higher than post-intervention production (p = .022).
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Figure 11. Stimulated tumor necrosis factor-α. Values expressed as mean ± standard
deviation. * indicates a main effect for time (p = .022) where pre-intervention was higher
than post-intervention. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir
group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).
With both KEF and CON groups combined, TNF-α production per monocyte
ranged from 3.76 to 99.40 fg/monocyte with an average of 40.54 ± 38.95 fg/monocyte at
the pre-intervention time point (see Figure 12). No significant main effects or
interactions were observed.
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Figure 12. Stimulated tumor necrosis factor-α production per monocyte. Values
expressed as mean ± standard deviation. There were no significant main effects or
interactions. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir group postintervention), CON-PRE (Control group pre-intervention), CON-POST (Control group
post-intervention).

Monocyte Counts
Total monocyte counts, when both KEF and CON groups were combined,
averaged 0.31x109 ± 0.17x109 cells/L at the pre-intervention time point, and 0.29x109 ±
0.17x109 cells/L at the post-intervention time point. A significant main effect for time
was observed where pre-intervention counts were 6.4% higher than post-intervention
counts (p = .001; see Table 4).
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Table 4
Monocyte Counts
KEF-PRE
(n = 9)

KEF-POST
(n = 9)

CON-PRE
(n = 10)

CON-POST
(n = 10)

Monocytes/L

0.35x109
±
0.15x109

0.36x109 *
±
0.22x109

0.27x109
±
0.18x109

0.23x109 *
±
0.09x109

Classical
Monocytes/L

0.25x109
±
0.02x109

0.26x109
±
0.02x109

0.18 x109
±
0.02x109

0.14x109
±
0.02x109

Non-Classical
Monocytes/L

0.07x109
±
0.02x109

0.04x109
±
0.01 x109

0.05 x109
±
0.01 x109

0.03 x109
±
0.01 x109

0.03x109
0.06x109
0.04 x109
0.06 x109
±
±
±
±
9
9
9
0.01 x10
0.01 x10
0.01 x10
0.01 x109
Note. Values expressed as mean ± standard deviation. * indicates a main effect for time
(p = .001) where pre-intervention counts were elevated when compared to postintervention. KEF-PRE (Kefir group pre-intervention), KEF-POST (Kefir group postintervention), CON-PRE (Control group pre-intervention), CON-POST (Control group
post-intervention).
Intermediate
Monocytes/L

Monocytes Percentage
The portion of immune cells that were monocytes, when KEF and CON groups
were combined, ranged from 0.5 to 3.22% with an average of 1.75 ± 0.74% (see Figure
13) at the pre-intervention time point. There were no significant main effects or
interactions. A notable correlation was observed when KEF and CON groups were
combined at the pre-intervention time point; there was a significant positive correlation
between total monocyte percentage and VO2peak (r = 0.483, N = 19, p = .036).
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Figure 13. Total percent of immune cells that are monocytes. Values expressed as mean
± standard deviation. There are no significant main effects or interactions. KEF-PRE
(Kefir group pre-intervention), KEF-POST (Kefir group post-intervention), CON-PRE
(Control group pre-intervention), CON-POST (Control group post-intervention).

Monocyte Phenotypes
Whole blood ranged from 48% to 82.36% classical monocytes with an average of
63.56 ± 8.67% categorized as classical monocytes, when KEF and CON groups were
combined at the pre-intervention time point. There was a significant time by group
interaction where KEF-PRE (p=0.002) experienced a 14.2% increase in the percent of
whole blood monocytes that were categorized as classical monocytes while the CON
remained relatively unchanged (see Figure 14).
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Figure 14. Percent of monocytes that are classical monocytes. Values expressed as the
mean ± standard deviation. * indicates a time by group interaction (p = .002) where KEFPRE was elevated compared to KEF-POST. KEF-PRE (Kefir group pre-intervention),
KEF-POST (Kefir group post-intervention), CON-PRE (Control group pre-intervention),
CON-POST (Control group post-intervention).

Whole blood ranged from 4% to 25.94% with an average of 10.31 ± 5.76%
categorized as non-classical monocytes when KEF and CON groups were combined at
the pre-intervention time point. A significant time by group interaction was observed
where KEF-PRE (p = .016) experienced a 22.5 % decrease in the percent of whole blood
monocytes categorized as non-classical monocytes while CON remained unchanged (see
Figure 15). A notable correlation was observed with KEF and CON groups combined at
the pre-intervention time point where there was a significant inverse correlation between
non-classical monocytes and body fat percent (r = -0.477, N = 19, p = 0.039).
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Figure 15. Percent of monocytes that are non-classical monocytes. Values are mean±
standard deviation. * indicates a time by group interaction (p = .016) where KEF-PRE
was elevated compared to KEF-POST. KEF-PRE (Kefir group pre-intervention), KEFPOST (Kefir group post-intervention), CON-PRE (Control group pre-intervention),
CON-POST (Control group post-intervention).

Whole blood ranged from 13.5% to 41.6% with an average of 26.5 ± 8.8%
categorized as intermediate monocytes when KEF and CON groups were combined at the
pre-intervention time point. A significant main effect for time was observed where both
KEF and CON groups combined experienced a 17.6% decrease in the percent of whole
blood monocytes categorized as intermediate (p = .02; see Figure 16). A notable
correlation was observed with both KEF and CON groups combined at the preintervention time point where there was a significant inverse correlation between
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intermediate monocyte percentage and the Piper Fatigue Scale (Piper et al., 1998) score
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(r = 0.576, N = 19, p = .01).

Figure 16. Percent of monocytes that are intermediate monocytes. Values are mean±
standard deviation. * indicates a main effect for time (p=0.02) where pre-intervention was
higher than post-intervention. KEF-PRE (Kefir group pre-intervention), KEF-POST
(Kefir group post-intervention), CON-PRE (Control group pre-intervention), CON-POST
(Control group post-intervention).
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CHAPTER V
DISCUSSION
Chemotherapy and radiation therapy have been associated with severe side effects
including altered immune function, gut health, and systemic inflammation (Bower et al.,
2011; Mego et al., 2013; Montassier et al., 2014; Standish et al., 2008). Exercise is an
effective modality to improve inflammation (Petersen & Pedersen, 2005) and recently,
the ability of probiotics to modulate the immune system is gaining attention (Lozupone et
al., 2013; Slattery, Cotter, & O'Toole, 2019; Tang et al., 2016; Tang, Xing, Li, Wang, &
Wang, 2017). Because of the potent probiotic content found in kefir, it presents itself as
a beneficial option for improving the immune system in cancer patients who have
undergone chemotherapy or radiation therapy. However, research examining the effects
of exercise training in conjunction with kefir supplementation was lacking, especially in
cancer survivors. Accordingly, the purpose of this study was to explore the effects of 12
weeks of kefir consumption on circulating biomarkers of inflammation (IL-6, TNF-α, and
CRP), a biomarker of gut dysbiosis (LPS), and monocyte phenotype and function in
active cancer survivors. These results were compared to a similar group of non-kefir
consuming cancer survivors
In this chapter, the results of the study are compared to findings in the literature.
Additionally, limitations of the study design and a conclusion of the results are discussed.
This chapter highlights descriptive measures of the participants, measures of dairy and
fermented food consumption, aerobic fitness and muscular strength measures, serum
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CRP, IL-6, and LPS, stimulated cytokine production, and finally monocyte counts and
phenotypes.
Body Size and Composition
Both KEF and CON groups were similar with respect to pre-intervention height
and weight. When KEF and CON groups were combined, height averaged 165.6 cm and
weight averaged 76 kg. Following the intervention, no main effect or interactions were
observed with respect to either height or weight in either KEF or CON. When both KEF
and CON groups were combined, body fat percent at the pre-intervention and postintervention time points was considered unhealthy in both KEF and CON groups with an
average of 36.43% at the pre-intervention time point, placing them in the obese category
Riebe, Ehrman, Liguori, & Magal, 2018; Schmitz et al., 2010). At the pre-intervention
time point, KEF was considered obese (37.1%), with only two of nine considered healthy
and the majority (seven of nine) considered obese. At the pre-intervention time point, the
average for CON was considered obese (35.9% body fat) with the majority 60% (6/10) in
the obese category, 30% (3/10) were at a healthy body fat percentage, and one participant
was underweight.
There was a significant time by group interaction where KEF experienced a
significant 10.7% reduction in body fat and there were no significant changes in CON by
the post-intervention time point. After the intervention time period, the majority of KEF
(six of nine) were still considered obese. It was possible the high diary consumption in
KEF helped reduce body fat and a number of reasons have been postulated as to why
dairy has a positive effect on body fat (Christensen et al., 2009; Ilich et al., 2019; Zemel,
2005). It was also possible the probiotics in kefir might have acted to help reduce body
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fat (Gomes et al., 2017; Kim et al., 2011). A full discussion of both of these topics is
present in the dairy and fermented food sections.
Furthermore, by the end of the intervention, a significant main effect for time and
a time by group interaction were observed with respect to lean body mass. More
specifically, at the pre-intervention time point, with KEF and CON groups combined,
average lean body mass was 48.5 kg; following the intervention, when both KEF and
CON groups were combined, they experienced a significant 4.4% increase in lean body
mass. Additionally, the group by time interaction revealed KEF experienced a significant
8.4% increase in lean body mass while CON experienced a significant 1.2% increase in
lean body mass.
The results from the present study suggested both exercise and kefir could
improve lean body mass. The increase in lean body mass observed in CON was similar
to that in other human studies (Stonehouse et al., 2016). For example, when frail older
adults underwent three months of supervised, progressive resistance training, there was
an average increase in lean body fat of 0.84kg (Binder et al., 2005). Conversely, kefir
improved lean body mass beyond what was observed in CON. This significant increase
in lean body mass in KEF was postulated to be in part due to the high leucine content
associated with whey protein in dairy. Leucine is an essential amino acids that triggers
muscle protein synthesis following exercise (Norton & Layman, 2006). Additionally,
this study showed exercise was an effective modality for improving lean body mass but
the inclusion of dietary kefir post exercise could have helped to increase lean body mass
beyond the improvements that were most likely associated with exercise. Together, data
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from the present study suggested exercise might help to improve lean body mass and the
addition of kefir consumed post exercise would improve body fat and lean body mass.
Aerobic Fitness and Muscular Strength
The supervised, individualized, structured exercise training program appeared to
significantly improve all aerobic fitness and muscular strength outcome measures for
both groups. Following the intervention, a significant main effect for time was observed
in VO2peak, chest press strength, lat pulldown strength, and leg press strength measures.
However, kefir did not appear to confer any additional improvements with respect to
these outcomes beyond those experienced by the control group. Prior to the intervention,
VO2peak for both KEF and CON groups combined averaged 23.55 ± 8.0 ml/kg/min
placing them in the poor category for healthy adults (Riebe et al., 2018) but placed them
in an above average for cancer survivors by the norms established by the UNCCRI
(Schneider et al., 2014). At the post-intervention time point, when KEF and CON groups
were combined, an average VO2peak had improved significantly; however, the average
value of 25.59 ± 7.56 ml/kg/min placed them in the same norm categories. As expected,
muscular strength measures were also considered above average for cancer survivors
with chest press strength pre- (46.1kg) and post-intervention (50.8kg), lat pulldown
strength pre- (47.5kg) and post-intervention (54.6kg), and leg press strength pre(106.3kg) and post-intervention (124.6kg; Arem et al., 2016). For example, when
examining the breast cancer survivors in the present study, chest press and leg press
strength at the pre-intervention time point were on average 23% and 11% greater,
respectively, when compared to breast cancer survivors in a similar study, which had
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completed 12-weeks of structured, supervised resistance training (Foley & Hasson,
2016).
Moreover, the lack of improvement in VO2peak and muscular strength in the KEF
group beyond the CON group was similar to a study where recreational runners
consumed kefir twice per week in combination with 15-weeks of intense marathon
training (O'Brien et al., 2015). The 15-weeks of marathon training improved VO2max in
both the kefir and exercising control groups; however, kefir did not improve VO2max
beyond that of the control group (O'Brien et al., 2017). It is important to note the present
study did not include non-exercising control groups. It is possible the inclusion of kefir
ingesting and non-kefir ingesting, non-exercising control groups would allow for a more
definitive answer as to whether (a) the exercise intervention truly improved the aerobic
fitness and muscular strength outcomes as well as all other CON group outcomes in this
study and (b) whether kefir could help improve aerobic fitness and muscular strength
outcomes in those who were not currently exercising.
Additionally, perhaps in the future, a longer intervention period would allow for
kefir to have a more significant effect on aerobic fitness or muscular strength beyond
what was observed in the present study. In summary, the present study helped to support
the well-established notion that exercise improves aerobic fitness and muscular strength
in cancer survivors. Kefir did not appear to confer measurable improvements beyond the
control group. Further research is needed to fully elucidate the effects of kefir
supplementation on aerobic fitness and muscular strength in exercising cancer survivors.
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Instruments
Beck Depression Inventory
The BDI is a survey that scores depression from 0 to 63 with 0-13 indicating
minimal depression, 14-19 indicating mild depression, 20-28 indicating moderate
depression, and 29-63 indicating severe depression (Eskelinen & Ollonen, 2011). At the
pre-intervention time point, when both KEF and CON groups were combined, the
majority of participants (17/19) were considered minimally depressed with an average
score of 7.2 with only 2 of 19 participants considered mildly depressed with scores of 15
and 18 (Eskelinen & Ollonen, 2011). Following the intervention, a significant main
effect for time was observed and when both KEF and CON groups were combined, there
was a significant 37.9% reduction in average BDI score and, at this time point, all
participants (19/19) were considered minimally depressed with an average score of 4.4.
Consequently, despite the lack of a non-exercising control group, it appeared exercise
could improve depression in cancer survivors. This concept was further supported where
12-weeks of a supervised exercise program with aerobic and resistance training
components significantly reduced BDI scores in breast cancer survivors (Ergun, Eyigor,
Karaca, Kisim, & Uslu, 2013). Although the mechanism was unclear, it was
hypothesized one mechanism might be related to the fact that both acute and chronic
exercise increased β-endorphin release, which might be associated with reductions in
depression and anxiety (Carr et al., 1981; Farrell, Gates, Maksud, & Morgan, 1982). To
summarize, the data in the present study suggested exercise could help improve
depression in cancer survivors. Kefir did not appear to play a significant role in the
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reduction of depression beyond that of the control group; however, future research is
needed to more fully elucidate the effects of kefir on depression in cancer survivors.
Piper Fatigue Scale
The Piper Fatigue Scale (Piper et al., 1998) ranges from 0 to 10 with 0 indicating
no fatigue, 1-3 indicating mild fatigue, 4-6 indicating moderate fatigue, and 7-10
indicating severe fatigue. When the KEF and CON groups were combined, the average
for all participants (which was 4) at the pre-intervention time point was considered
moderately fatigued (Piper et al., 1998). Following the intervention, a main effect for
time and a group by time interaction were observed. There was a significant 22.3%
reduction in mean fatigue score when both KEF and CON groups were combined,
resulting in a reduction from the moderate fatigue category to the mild fatigue category
with an average score of 3.1 (Piper et al., 1998). Conversely, after the intervention, the
KEF group experienced a significant 40.5% reduction in fatigue score while the CON
group experienced a non-significant 6% reduction in fatigue score.
The results from the present study suggested exercise reduced fatigue in cancer
survivors and this was well established in the literature (Cantarero-Villanueva et al.,
2013; Meneses-Echávez, González-Jiménez, & Ramírez-Vélez, 2015). It was proposed
exercise helped to reduce activity of NF-κB, which resulted in a reduction of
inflammatory biomarkers and, in turn, was related to reductions in fatigue associated with
cancer (Antoni et al., 2012; Fairey et al., 2005; Kangas, Bovbjerg, & Montgomery,
2008). Still, it appeared kefir conferred benefits beyond those experienced with exercise.
Although the effect of kefir on cancer-related fatigue has not been previously studied in
humans, four weeks of kefir supplementation in normal healthy mice acted to change the
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gut microbiota, which reduced exercise-induced fatigue (Hsu et al., 2018). The authors
suggested this effect was related to significant reductions in serum concentrations of
lactate, creatine kinase, and ammonia (Hsu et al., 2018). These results and the
observations related to fatigue in the present study suggested more research focused on
kefir and fatigue is needed. To summarize, data from the present study supported that
idea that exercise was a beneficial modality in improving cancer-related fatigue and
suggested the use of kefir post exercise might help to further reduce feelings of fatigue.
Quality of Life Index
Quality of Life Index (Rustoen et al., 1999) scores ranged from 0 to 30 with 30 as
an indicator of maximal life satisfaction. Both KEF and CON groups combined at the
pre-intervention time point averaged a total QOL score of 22.5 out of maximum of 30,
which is considered high (Ferrans & Powers, 1992). In fact, the scores observed in the
present study were 5% higher than values in a study that explored quality of life in cancer
patients who were recently diagnosed (Rustoen et al., 1999). No significant main effects
or interactions were observed in the present study. However, at the post-intervention
time point, there was a small (3.2%) increase in QOL scores when KEF and CON groups
were combined but this increase was not statistically significant. The high level of QOL
scores in the present study might have limited the ability of participants to significantly
improve their quality of life. Despite the lack of significance, the slight increase in QOL
scores might be attributed to the exercise intervention. It is well established that exercise
improves the quality of life in cancer patients who have undergone chemotherapy or
radiation therapy (Carayol et al., 2013; Haines et al., 2010). For example, just five weeks
of a three session per week supervised aerobic and resistance training program
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significantly improved quality of life in breast cancer patients undergoing radiation
therapy (Hwang et al., 2008). The kefir intervention resulted in a 3.7% increase in scores
whereas the control group experienced a 3.5% increase in scores after the intervention.
Although these changes were not considered significant, a longer intervention period with
individuals who are sedentary and have a lower quality of life might maximize the
potential to more fully explore whether kefir has an effect on overall quality of life. In
summary, data from the present study revealed no differences related to exercise or kefir
treatment. However, these results might help to initiate the conversation in the research
community about the use of kefir to improve quality of life in cancer patients.
Dairy Consumption
At the pre-intervention time point, both KEF and CON groups combined
consumed dairy products approximately four days per week and most frequently reported
consuming cheese and yogurt. However, it is important to note that the KEF group
consumed dairy significantly (57%) more frequently than did the CON group at the preintervention time point, which might have limited the ability of a dairy intervention to
improve outcome variables in the kefir group. This result coupled with the fact the KEF
group experienced a statistically significant 10.7% reduction in body fat percent at the
post-intervention time point is a reason for further inquiry. Kefir has low lactose
concentrations, which make it an attractive option for cancer survivors who enjoy dairy
and would like to potentially use it as a method of improving body composition. Several
reasons are postulated as to how dairy acts to reduce body fat. It is hypothesized that
increased calcium intake from dairy products could reduce lipogenesis and stimulate
lipolysis by suppressing formation of 1,25 dihydroxyvitamin D and secreting parathyroid
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hormone or calcitropic hormone (Zemel, 2005). Another suggested mechanism of
calcium induced body fat loss is calcium binds with fatty acids in the intestine to form
insoluble soaps that absorb fat (Christensen et al., 2009). Together, these results, in
addition to the observed increases in lean body mass, suggest kefir might be a beneficial
dairy option for cancer patients who would like to improve body composition.
Fermented Food
Prior to the intervention, all participants consumed on average two different
fermented foods approximately four times per week. The most frequently consumed
foods were yogurt, pickles, and beer or wine. Yogurt was consumed the most frequently
with reports averaging approximately four times per week, while alcoholic beverages like
beer or wine were consumed on average one to two times per month. Consequently, it
appeared participants in the present study were consuming healthier forms of fermented
foods more frequently than unhealthy fermented foods prior to the intervention.
Interestingly, although the participants in the present study appeared to be consuming
healthy fermented foods prior to the intervention period, there were significant positive
correlations between fermented food consumption and body fat percent with KEF and
CON groups combined at the pre-intervention time point. Conversely, in other studies,
fermented foods led to a reduction in body fat. For example, in a study examining the
effects of four weeks of kimchi (the fermented cabbage dish) consumption, there were
significant reductions in body fat percent in overweight and obese individuals (Kim et al.,
2011). Furthermore, in support of this notion, the KEF group in the present study
experienced a significant 10.7% reduction in body fat following the intervention. These
results were similar to a study examining the effects of the probiotics Lactobacillus.

95
reuteri in overweight and obese individuals. When the participants ingested the probiotic
once per day for 12 weeks, they experienced a significant reduction in body fat (Chung et
al., 2016). Furthermore, when overweight and obese women consumed a probiotic
mixture (L. acidophilus, L. casei, L. lactis, B. bifidum, and B. lactis) seven times per
week for eight weeks, they experienced a significant reduction in measures of abdominal
adiposity (Gomes et al., 2017).
Although the mechanism for these actions was unclear, one hypothesis was
probiotics could reduce dietary fat and free fatty acid absorption in the small intestine,
leading to increased excretion of the free fatty acids (Chung et al., 2016). This was
thought to be accomplished through the regulation of Sterol regulatory element-binding
protein 1, Acetyl-CoA Acetyltransferase, apoptosis antigen 1, and Peroxisome
proliferator-activated receptor-α genes associated with reducing lipogenesis and
increasing beta oxidation (Mei et al., 2015). To summarize, the present study suggested
the probiotic component of kefir might be effective in conjunction with other aspects of
the dairy beverage in reducing body fat in cancer survivors.
Gastric Distress
Prior to the intervention, when the KEF and CON groups were combined, all
participants on average experienced relatively low GI distress (11/60) with the most
common disturbances related to gas/flatulence, regurgitation/reflux, and urge to defecate.
After the intervention, a significant main effect for time and time by group interaction
occurred. At the post-intervention time point, both KEF and CON groups combined
experienced a significant 42.7% reduction in GI distress score with the KEF group
reporting an average and significantly different 64.7% reduction in GI distress score
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when compared to the CON group reporting an average 14.3% reduction in GI distress
score. These results suggested the exercise program might have reduced reports of GI
distress but the use of kefir in combination with exercise more drastically reduced reports
of GI distress. The reduction in GI distress as the result of an exercise was supported by
other studies. Some studies suggested acute exercise might be beneficial in alleviating GI
distress in healthy individuals and chronic exercise might be beneficial in alleviating GI
distress in individuals with inflammatory bowel disease (Johannesson, Simrén, Strid,
Bajor, & Sadik, 2011; Villoria, Serra, Azpiroz, & Malagelada, 2006).
Interestingly, in the present study, kefir reduced GI distress beyond exercise
alone; however, a non-exercising control group would be essential to fully explore this
phenomenon. The improvement in the KEF group was further supported by other studies
that suggested kefir could reduce reports of GI distress in humans (Lozupone et al., 2013;
Yılmaz, Dolar, & Özpınar, 2019). For example, in a study examining the effect of kefir
supplementation on Chron’s disease and ulcerative colitis, four weeks of kefir
supplementation significantly reduced disease-related symptoms and improved the
quality of life (Yılmaz et al., 2019). Additionally, in the present study, prior to the
intervention, there was a strong inverse correlation between GI distress and fermented
food consumption. Previous research suggested fermented foods could improve
gastrointestinal tract health by improving bacterial composition, which helped to
modulate immune response and reduce the intestinal inflammation that leads to GI
distress (Lozupone et al., 2013). Data from the present study suggested exercise might be
a beneficial modality to improve gastric distress in cancer survivors who have undergone
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chemotherapy or radiation; however, when exercise was coupled with kefir consumption,
there appeared to be a more significant reduction in reports of GI distress.
Serum Interleukin-6
Resting and fasted serum IL-6 concentrations in the KEF and CON groups
combined were not different at the pre-intervention time point and, following the
intervention, no main effects for time or time by group effects were observed. Serum IL6 concentrations, when both KEF and CON groups were combined, were within the
normal range for healthy individuals (5-15 pg/ml) at both time points of the intervention
(Alecu, Geleriu, Coman, & Gălăţescu, 1998; Angulo et al., 2017; Kumari et al., 2016). It
is important to note that changes might not have been observed in the KEF or CON
groups following the intervention due to the large variability observed in this study and
reported in others with respect to serum IL-6 concentrations in humans (Nilsonne,
Lekander, Åkerstedt, Axelsson, & Ingre, 2016; Picotte, Campbell, & Thorland, 2009).
When both KEF and CON groups were combined at the pre-intervention time
point, there was a significant inverse correlation between dairy consumption and serum
IL-6 concentrations. It was possible the increased dairy consumption in the KEF group
before the study began might have reduced the ability of kefir to exert a significant effect
on serum IL-6. Nevertheless, the relationship between dairy intake and IL-6 might be
attributed at least in part to the calcium found in dairy. When adult participants
consumed 800mg of calcium per day from dairy for three months, serum IL-6 was
significantly reduced (Stonehouse et al., 2016). It was believed calcium helped to inhibit
NADPH oxidase expression and ROS production, resulting in a reduction in
inflammatory cytokine production (Zemel & Sun, 2008). Although no significant main
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effects or interactions were observed in this study, it is possible a longer intervention with
individuals who were not regularly consuming dairy or probiotics might have yielded
different results.
Serum C-Reactive Protein
Serum CRP concentrations are used to assess systemic inflammation in a number
of chronic disease conditions and, most commonly, used to evaluate an individual’s risk
for CVD (Brooks, Blaha, & Blumenthal, 2010). Serum concentrations of CRP that are
less than 1 mg/L, 1-3 mg/L, and greater than 3 mg/L indicate a low, moderate, and high
cardiovascular risk, respectively (Ridker, 2003). In this study, no main effects for time or
time by group interactions were observed; neither exercise nor kefir significantly reduced
CRP concentrations and both means of the KEF and CON groups placed them at high
risk for developing CVD at both the pre-intervention and post-intervention time points.
More specifically, the average CRP concentration, when both KEF and CON groups were
combined, was 4.47 mg/L and 3.56 mg/L at the pre-intervention and post-intervention
time points, respectively. When the KEF and CON groups were combined at the preintervention time point, 11% (2/19) were at low risk for CVD, 37% (7/19) were
considered at moderate risk for CVD, and 52% (10/19) were considered at increased risk
for CVD (Ridker, 2003). Following the intervention when both KEF and CON groups
were combined, 11% (2/10) were still at low risk for CVD, 68% (13/19) were at
moderate risk for CVD, and only 21% (4/19) were at a high risk for CVD (Ridker, 2003).
Although post-intervention the mean CRP in the KEF group was still considered a
high risk for CVD and serum CRP concentrations were not significantly changed, it is
important to note the CRP concentrations were closer to a moderate risk than before the
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intervention (5.5mg/L to 3.51mg/L; Ridker, 2003). Furthermore, it is also important to
note that in the KEF group at the pre-intervention time point, one participant was a
significant outlier and the serum CRP in that participant was significantly elevated (48.17
mg/L) when compared to serum CRP concentrations typically observed at UNCRRI
(2.33mg/L; Christensen et al., 2019). Although this subject did not present for the blood
sample with any signs of acute sickness, it was not possible to determine the exact cause.
When the data were analyzed both with and without this participant, the results of the
study with respect to CRP were unchanged. It is important to note all results presented in
this document included this subject.
The results in the present study were somewhat similar to a study mentioned
earlier that examined the effects of kefir supplementation over the course of 15 weeks of
marathon training in recreational runners (O'Brien et al., 2015). Serum CRP
concentrations in the exercise control group were significantly increased following the
marathon training period while the kefir group experienced no significant changes in
serum CRP following the intervention (O'Brien et al., 2015). This study suggested kefir
might play a role in helping to control inflammation during periods of intensified
training. It is possible the exercise training experienced by the cancer survivors in the
present study was not intense enough to induce inflammation like those who were
marathon training in the study above. In fact, other studies reported the probiotics
associated with kefir, such as Lactobacillus. plantarum, had modest anti-oxidative effects
and appeared to upregulate glutathione peroxidase and superoxide dismutase activity to
increase free radicals catalyzation (Tang et al., 2016, 2017). It is postulated the high
scavenging ability of the exopolysaccharide of these bacteria played a role in these
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effects (Zhang et al., 2017). Future studies might need to further explore the ability of
specific bacterial strains to control inflammation in humans.
There is a well-established, positive relationship between CRP and body fat
(Oliveira, Lopes, Severo, Rodríguez-Artalejo, & Barros, 2011; Park, Park, & Yu, 2005).
In the present study with the KEF and CON groups combined at the pre-intervention time
point, there was a significant positive correlation between serum CRP and body fat
percentage. Fat tissue is considered a multifunctional organ that plays a role in the
release pro-inflammatory molecules, IL-6 and TNF-α, which, in turn, trigger hepatocyte
expression and release of CRP (Brooks et al., 2010) as well as local and systemic
inflammation (Moulin, Marguti, Peron, Rizzo, & Halpern, 2009). It is possible the
reduction in body fat observed in this study was not enough to reduce circulating
concentrations in CRP. Given the lack of time by group effect observed in this study and
the significant reduction in body fat observed in the KEF group, a longer intervention
might have been necessary to fully elucidate the effects of kefir on CRP.
Serum Lipopolysaccharide
At the pre-intervention time point, average serum LPS concentrations when the
KEF and CON groups were combined was 33.27 pg/ml. The average concentration in
the present study was similar to the mean serum LPS concentration of healthy controls
(35 pg/ml) in a study examining serum LPS and LPS binding protein in individuals with
sepsis (Zweigner, Gramm, Singer, Wegscheider, & Schumann, 2001). Interestingly,
patients with sepsis had serum LPS concentrations 2.6 times greater (86.5pg/ml) than the
average concentration of LPS in the present study when the KEF and CON groups were
combined at the pre-intervention time point. On the other hand, when the KEF and CON
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groups were combined, pre-intervention serum LPS concentrations in the present study
were 25.1% less than those observed in individuals with Chron’s disease (Guo et al.,
2015). Something to note, however, was almost one third of the participants (6/19) in the
present study had serum LPS concentrations similar to those observed in patients with
Chron’s disease and one participant had a serum LPS concentration similar to that in
patients with sepsis.
At the post-intervention time point, a significant time by group interaction was
observed where the KEF group experienced a significant 50.7% reduction in serum
concentrations of LPS, while the CON group experienced a non-significant increase of
3% after the intervention. Consequently, it appeared that 12 weeks of kefir consumption
drastically reduced serum LPS in cancer patients who had undergone chemotherapy or
radiation therapy. It is possible the reduction in serum LPS observed in the KEF group
was due to an improved intestinal barrier by way of increasing tight junctions (Anderson
et al., 2010; Caballero-Franco et al., 2007) and mucus production (Barcelo et al., 2000;
Mack et al., 2003), as well as increased protection against pathogens brought on by the
probiotics found in kefir (Bermudez-Brito, Plaza-Díaz, Muñoz-Quezada, GómezLlorente, & Gil, 2012; Saavedra, 2001; Serban, 2014). More specifically, probiotics like
Bifidobacterium, which are found in kefir, could enhance the expression of zona
occludens-1, a protein that forms tight junctions in the intestines (Ewaschuk et al., 2008;
Moorthy et al., 2009; Qin et al., 2005). Additionally, metabolites of these bacteria-like
short chain fatty acids are associated with a reduction in intestinal permeability and
increased epithelial cell viability (Venkatraman et al., 1999, 2003). Moreover, beneficial
bacteria-like probiotics could increase expression of mucus-related mucin 2 and mucin 3
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genes, resulting in increased mucus layer thickness. Furthermore, several metabolites
from beneficial bacteria, including some short-chain fatty acids including butyrate, which
was mentioned earlier, could regulate the production of cathelicidins, which could
provide broad-spectrum anti-bacterial activities against potential pathogens in addition to
reducing the ability of pathogens to colonize in the gut (Bermudez-Brito et al., 2012;
Müller et al., 2005; Saavedra, 2001; Serban, 2014). Although these mechanisms remain
to be fully elucidated, the present study suggested kefir might be beneficial for cancer
survivors who have undergone chemotherapy or radiation therapy and who are looking to
decrease serum LPS concentrations.
Stimulated Interleukin-6 Production
In the present study when whole blood samples were cultured with LPS, IL-6
production with both KEF and CON groups combined at the pre-intervention time point
(4.92 ng/ml) and post-intervention time point (4.98 ng/ml) was similar to that observed in
a study using the same protocol in post-menopausal obese women (Phillips et al., 2012).
Following the pre-intervention, there was a significant time by group interaction; and
post-intervention, when whole blood samples were cultured with LPS, the KEF group
experienced a significant 17.8% reduction in stimulated IL-6 when compared to the preintervention time point, while there were no significant changes in the CON group. This
reduction in the overall capacity of whole blood to produce IL-6 in the KEF group might
have been due to the kefir acting to improve the efficiency of the immune response to
bacterial stimuli. In fact, a study examining the effects of kefir- specific probiotic
lactobacillus strains showed that when immune cells were cultured with isolated
probiotics specific to kefir, there was a significant reduction in LPS stimulated IL-6
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production (Slattery et al., 2019). It is hypothesized these probiotics acted to prime the
immune system to protect against a bacterial infection, resulting in a more efficient
immune but reduced response to the stimulus (Slattery et al., 2019).
When IL-6 production was expressed per monocyte in the present study, the
values were much lower for pre-intervention (44.8 fg/monocyte) and post-intervention
(28.61 fg/ml) time points when the KEF and CON groups were combined and compared
to results from a study using the same protocol in post-menopausal obese women
(Phillips et al., 2012). Furthermore, a significant main effect for time was observed and
when both KEF and CON groups were combined, there was a significant 36.2%
reduction in stimulated IL-6 production per monocyte by the post-intervention time point.
This result suggested exercise training might optimize IL-6 production per monocyte.
Other studies supported this idea and some suggested exercise acted to decrease the
number of inflammatory monocytes as well as TLR4 expression on the surface of
immune cells (Gleeson, McFarlin, & Flynn, 2006). Moreover, a study with young and
old physically inactive individuals showed 12 weeks of combined resistance and aerobic
exercise training reduced IL-6 production per monocyte in both groups following LPS
stimulation (Stewart et al., 2005). After taking the results from this study and others into
consideration, kefir might help to optimize stimulated IL-6 production in cancer
survivors. Additionally, exercise appeared to reduce simulated IL-6 production when
expressed per monocyte in cancer survivors, which was also supported by the literature
(Gleeson et al., 2006; Phillips et al., 2012; Stewart et al., 2005).

104
Stimulated Tumor Necrosis Factor-α Production
When both KEF and CON groups were combined, the mean LPS stimulated TNFα production at the pre-intervention time point was similar to values reported in a similar
study with obese older women (Phillips et al., 2012). In the present study, a significant
main effect for time was observed and when both KEF and CON groups were combined,
they experienced a significant 28.2% reduction in stimulated TNF-α when compared to
the pre-intervention time point, which suggested regular exercise might help reduce
stimulated TNF-α production. The results in the present study were supported by a study
examining the effect of three months of yoga on inflammatory cytokine production in
breast cancer survivors. Following the three month yoga intervention, LPS stimulated
TNF-α was significantly reduced in breast cancer survivors (Kiecolt-Glaser et al., 2014).
Furthermore, a cross-sectional study in overweight postmenopausal women showed a
single bout of resistance exercise was capable of decreasing TNF-α production after LPS
stimulation in whole blood samples (Phillips et al., 2012). It was hypothesized that
exercise could reduce TLR4 expression on monocytes; thus, when monocytes were
stimulated with LPS, the inflammatory response was reduced (Flynn, McFarlin, Phillips,
Stewart, & Timmerman, 2003; McFarlin, Flynn, Campbell, Stewart, & Timmerman,
2004)
In the present study, average TNF-α production per monocyte when both KEF
and CON groups were combined at pre-intervention (40.54 fg/monocyte) and postintervention, time points (28.24 fg/monocyte) were similar to those observed in a study
using the same protocol in older obese women (Phillips et al., 2012). Following the
intervention, there were no main effects for time or time by group interactions. However,
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when the KEF and CON groups were combined, there was a non-significant 28%
reduction in TNF-α production per monocyte. It is possible the larger variability or
already lower concentration of TNF-α production per monocyte was responsible for the
lack of significance observed in the present study. In the current study, there were no
differences between or within groups with respect to kefir consumption. It is possible
kefir might be working through a different mechanism of action. In summary, the current
study suggested exercise might reduce stimulated TNF-α in cancer survivors who have
undergone chemotherapy or radiation therapy but there was no evidence that kefir might
improve this outcome in cancer survivors.
Monocyte Counts
Total monocyte counts when both KEF and CON groups were combined
averaged 0.31x109 cells/L at the pre-intervention point. At the post-intervention time
point, there was a significant time effect where when both KEF and CON groups were
combined and a 6.4% reduction in monocyte counts. It is important to note that both
mean monocyte counts in both KEF and CON groups were still within a normal range at
both the pre-intervention and post-intervention time points (Nazir et al., 2016).
Furthermore, following the intervention, there was a non-significant 1% increase in the
KEF group while the CON group experienced a non-significant 15.1% reduction.
These findings suggested kefir might be effective in improving the immune
system with respect to monocyte counts. The findings in the present study opposed
findings of other studies in humans that demonstrated no change in monocyte count after
ingesting probiotics (D'Angelo, Reale, & Costantini, 2017; Horvath et al., 2016).
However, one study found that when otherwise healthy older adults were given milk
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containing probiotics for eight weeks, there were no changes in monocyte number but
kefir was able to significantly improve the phagocytizing and oxidative burst capabilities
in monocytes (Parra, De Morentin, Cobo, Mateos, & Martinez, 2004). Furthermore, a
study examining the effect of eight weeks of Lactobacillus plantarum probiotic
supplementation on leukocyte counts in sturgeon showed the probiotic supplementation
significantly increased monocyte count while the untreated control showed no change
(Pourgholam, Kharra, Safari, Sadati, & Aramli, 2017). The mechanism behind these
changes was not entirely clear. Nevertheless, most researchers agreed probiotics have
immunomodulatory effects that could help to optimize immune cell numbers and
efficiency (Pourgholam et al., 2017). Data from the present study suggested both
exercise and kefir might improve monocyte numbers in cancer patients who have
undergone chemotherapy and radiation therapy.
Monocyte Percentage
At the pre-intervention time point when both KEF and CON groups were
combined, average monocyte percentage, which was 1.75%, classified study participants
as monocytopenic, which was defined as less than 2% of all immune cells categorized as
monocytes (Kasper & Harrison, 2005; Seidler et al., 2010). This low percentage of
monocytes was likely a result of chemotherapy and radiation therapy. In a study
examining the effects of different chemotherapies on immune cells, chemotherapy
treatment significantly reduced monocytes in individuals with a variety of different
cancers (Nazir et al., 2016). Moreover, chemotherapy reduced monocytes counts to a
level of monocytopenia in 75% of participants. Furthermore, in breast cancer patients
undergoing radiation therapy, radiation treatment induced a significant and prolonged
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reduction in whole blood monocytes, which continued to decrease beyond the end of the
six week study (Standish et al., 2008).
In the present study, no significant post-intervention changes were observed with
respect to total monocyte percentage in either the KEF or CON groups. Despite this lack
of significance, the KEF group experienced a non-significant 26.8% increase in whole
blood total monocyte percentage following the intervention (p =.057). Still, postintervention, the KEF group improved from a category of monocytopenia (<2%) to a
healthy range (2-8%) with an average of 2.3% of all immune cells (Kasper & Harrison,
2005; Seidler et al., 2010).
At the pre-intervention time point with both KEF and CON groups combined,
there was a significant positive correlation between total monocytes and VO2peak. This
interesting finding in the present study was supported by a study examining exercise
capacity in patients with permanent atrial fibrillation where total monocytes were
positively associated with VO2peak and maximum exercise capacity (Kahn, Shahid, Lip,
& Shantsila, 2018). However, it appeared the majority of studies suggested monocyte
numbers were inversely related to aerobic fitness. For example, in a study exploring the
relationship between cardiovascular fitness and inflammatory markers in overweight
women, it was shown monocyte counts were inversely correlated with VO2max
(Michishita, Shono, Inoue, Tsuruta, & Node, 2008). It was hypothesized the inverse
relationship was due to the role leukocytes played in the development and progression of
atherosclerosis; however, the mechanism linking these factors together was unknown
(Michishita et al., 2008). To summarize, data from the current study suggested kefir
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might have the potential to help improve the total percent of immune cells that are
monocytes in cancer survivors who have undergone chemotherapy or radiation therapy.
Classical Monocytes
At the pre-intervention time point, both KEF and CON groups were below the
normal healthy range of 80-95% for monocytes categorized as classical monocytes with
an average range of 63.56% (Bradfield et al., 2007; Randolph et al., 2002; Shi & Pamer,
2011; Wong et al., 2011). There was a significant group by time effect where the KEF
group experienced a significant 14.9% increase in the percent of monocytes that were
classical monocytes. Despite the significant increase in the KEF group, the percent of
classical monocytes following the intervention had not increased enough to bring the
KEF group to a normal healthy range (Bradfield et al., 2007; Randolph et al., 2002; Shi &
Pamer, 2011; Wong et al., 2011). Moreover, the CON group did not experience
improvements in percentage of classical monocytes.
It is important to note that in disease states and times of infection, the percent of
monocytes that are classical typically either remains the same or slightly decreases (Shi
& Pamer, 2011; Wong et al., 2011). It appears kefir was able to improve the percent of
monocytes that were classical in a manner that suggested the KEF group was recovering
from a disease state. In fact, when probiotic supplementation was used to combat agerelated decline in immune function, ingestion of milk with the probiotic Bifidobacterium
lactis increased classical monocyte percentages when compared to milk without
probiotics (Gill, Rutherfurd, Cross, & Gopal, 2001). The mechanisms by which
probiotics influenced the functioning of the immune system are not fully understood.
However, it appeared that recognition of probiotic pathogen-associated molecular
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patterns by PRRs, such as toll-like receptors present on the surface of immune cells,
might trigger the release of a range of cytokines that shape the developing immune
response and can alter monocyte phenotype (Gill, 1998, 2003; Meydani & Ha, 2000). To
summarize, the data in the present study suggested kefir might improve the percentage of
monocytes that are classical in cancer survivors who have undergone chemotherapy or
radiation therapy; however, the specific mechanism of action has yet to be fully
described.
Non-Classical Monocytes
At pre-intervention time point, the KEF group was above a normal range for the
percent of monocytes considered non-classical, which is 2-8%, with an average of
12.05% (Bradfield et al., 2007; Randolph et al., 2002; Shi & Pamer, 2011; Wong et al.,
2011) while the CON group was at a normal healthy range with an average of 8.7% of
monocytes considered classical (Bradfield et al., 2007; Randolph et al., 2002; Shi &
Pamer, 2011; Wong et al., 2011). There was a significant time by group interaction at the
post-intervention time point where the KEF group experienced a significant 22.5%
reduction in percent of monocytes that were non-classical to slightly above a normal
healthy range with an average of 9.3%. On the other hand, the CON group experienced a
non-significant 49.6% increase in percent of monocytes that were non-classical at the
post-intervention time point ,which placed the average for the CON group in the elevated
range for percent of monocytes considered non-classical (2-8%; Bradfield et al., 2007;
Randolph et al., 2002; Shi & Pamer, 2011; Wong et al., 2011). It is possible the large
increase observed in the CON group was not significant due to large variability in the
monocyte phenotype. Perhaps in the future, an additional biomarker should be
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considered when differentiating between monocyte phenotypes. Nonetheless, this
suggested kefir might play a role in the reduction of inflammatory monocytes.
Furthermore, when the KEF and CON groups were combined, there was a
significant inverse correlation between non-classical monocytes and body fat percent at
the pre-intervention time point. The relationship observed in the present study was
contradictory to findings in another studies. For example, in a study examining the
monocyte populations in obese individuals and individuals with subclinical
atherosclerosis, adiposity was directly related to increased numbers of inflammatory
monocytes (Rogacev et al., 2010). Moreover, when female mice were fed a high fat diet
to induce obesity, there was a positive correlation between increased fat mass and
inflammatory monocytes (Béliard et al., 2017). It was postulated excess body fat could
increase the expression of monocyte chemoattractant protein-1, which is a proinflammatory cytokine that could result in increased numbers of inflammatory monocytes
(Christiansen, Richelsen, & Bruun, 2005; Kanda et al., 2006). Although future
investigation is needed to more fully explore this relationship, the present study
suggested kefir might be effective in reducing non-classical monocytes in cancer
survivors who have undergone chemotherapy or radiation therapy.
Intermediate Monocytes
At the pre-intervention time point when both groups were combined, participants
had a high percent of monocytes that were intermediate with an average of 26.5%, which
was more than double the normal healthy range of 2-11% (Bradfield et al., 2007;
Randolph et al., 2002; Shi & Pamer, 2011). The average percent of monocytes that were
intermediate in the present study was 24% higher than observed in a study examining the
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effects of cancer on inflammatory monocytes in breast cancer patients (Qian et al., 2011).
However, it is important to note that in the affirmentioned study, none the participants
underwent any cancer-related treatment prior to the study. It is possible that in the
present study, the chemotherapy or radiation treatments all participants underwent could
have induced a greater increase in intermediate monocytes. This was supported by
another study that found chemotherapy induced a rapid 55% increase in intermediate
monocytes in individuals with colorectal cancer (Qian et al., 2011; Schauer et al., 2016).
Although there were no significant group effects or interactions, there was a
significant main effect for time with respect to percent of monocytes that were
intermediate in the present study. Following the intervention when both KEF and CON
groups were combined, they experienced a significant 17.6 % decrease in intermediate
monocytes when compared to the pre-intervention time point. However, at that time
point, both KEF and CON groups still had an elevated percent of monocytes considered
intermediate. When both KEF and CON groups were combined at the post-intervention
time point, the average percent of monocytes that were intermediate was 22.5%
(Bradfield et al., 2007; Randolph et al., 2002; Shi & Pamer, 2011). This suggested that
although cancer and/or treatment significantly increased intermediate monocytes,
exercise might be a beneficial modality to help improve these inflammatory cells. This
finding related to intermediate monocytes and exercise was supported by another study
where 12 weeks of supervised combined aerobic and resistance exercise significantly
reduced the percent of monocytes that were inflammatory in older adults (Timmerman et
al., 2008).
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Furthermore, at the pre-intervention time point with both KEF and CON groups
combined, there was a significant inverse correlation between intermediate monocytes
and the Piper Fatigue Scale (Piper et al., 1998) score. It is possible the lower percentage
of intermediate monocytes caused a decrease in inflammatory cytokine release, leading to
a reduction in fatigue. A study examining the relationship between TNF-α released by
monocytes and fatigue in cholestatic mice showed activated inflammatory monocytes
could enter into the brain and secrete TNF-α to induce fatigue (Kerfoot et al., 2006).
Additionally, in breast cancer survivors who underwent some form of cancer treatment,
circulating TNF-α appeared to be a significant contributor to treatment-related fatigue
both during and after treatment (Geinitz et al., 2001; Von Ah, Kang, & Carpenter, 2008;
Wratten et al., 2004). To summarize, both longitudinal and correlation data from the
present study suggested exercise might be a beneficial modality to improve intermediate
monocytes in cancer survivors who have undergone chemotherapy or radiation therapy.
Limitations
A few note-worthy limitations to this study mentioned earlier should be further
explained here. The sample size was relatively small and, in some cases, this limitation
was thought to be the reason for this researcher’s inability to detect significant
differences among groups. Additionally, the types of cancer treatment and time since
treatment varied among participants. Moreover, cancer stage and type varied among
individuals; however, this variety provided a more realistic idea as to how cancer
survivors reacted to exercise and kefir treatment. Furthermore, although kefir
consumption was monitored and participants were asked to recall their normal dietary
habits, all dietary activities were not monitored in the participants. Finally, both a non-
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exercising kefir group and a non-exercising non-kefir group would be needed to fully
elucidate the effects of kefir consumption and exercise intervention in cancer patients
who had undergone chemotherapy or radiation therapy. Furthermore, it is possible the
12-week intervention period was not long enough to produce significant results. Perhaps
including a large population with a specific cancer type and treatment as well as
increasing the intervention period time might have given more sufficient time for these
outcomes to more fully develop.
Conclusion
In conclusion, the hypotheses that 12 weeks of kefir consumption would reduce
the percent of inflammatory monocytes, reduce LPS stimulated IL-6 production, and
reduce serum LPS in active cancer survivors who had undergone chemotherapy and/or
radiation therapy within the past two years were supported while the hypotheses that 12
weeks of kefir consumption would reduce resting serum concentrations of inflammatory
biomarkers, total percent of immune cells that were monocytes, and LPS stimulated TNFα production in active cancer survivors who had undergone chemotherapy and/or
radiation therapy within the past two years were rejected. More specifically, following
12 weeks of supervised exercise training, a significant main effect for time was observed
with significant improvements in VO2Peak, muscular strength, and lean body mass in all
participants. Additionally, a significant time by group interaction was observed with the
KEF group experiencing a significant body fat percent reduction and a larger increase in
lean body mass compared to the CON group.
Significant main effects for time and time by group interactions were observed
where both KEF and CON groups significantly improved scores related to depression,
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fatigue, and gastric distress but kefir supplementation induced a greater reduction in
fatigue and gastric distress when compared to the control. No main effects or group
interactions were observed in serum concentrations of CRP or IL-6 but a significant time
group interaction was observed in the KEF group with a significant reduction in serum
LPS. Furthermore, a significant time by group interaction was observed in the KEF
group with a significant reduction in whole blood cultured stimulated IL-6 production. A
main effect for time was also observed with a reduction in stimulated IL-6 production per
monocyte in both KEF and CON groups. Additionally, a significant main effect for time
was observed for whole blood stimulated TNF-α production, which was reduced in both
KEF and CON group following the intervention but no main effects or interactions were
observed with respect to stimulated TNF-α production per monocyte. Still, following the
intervention, even though no significant main effects or interaction were observed, the
KEF group improved the total percent of immune cells that were monocytes in a nonsignificant manner to a healthy norm while the CON group experienced no change.
Moreover, a significant time by group interaction was observed where the KEF group
significantly improved its percent of monocytes that were classical and non-classical.
Furthermore, a significant main effect was observed where both KEF and CON groups
experienced a significant reduction in percent of monocytes that were intermediate.
While it has been established that exercise training could help improve many aspects of
cancer survivors’ lives, kefir appeared to be well-tolerated and has the potential to
improve body composition with respect to body fat and lean body mass, immune function
fatigue, and gastric distress. Perhaps including kefir as a post exercise dietary
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supplement with cancer survivors might be something cancer rehabilitation programs
should consider.
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CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH
Title: Kefir and the Control of Inflammation in Active Cancer Survivors (KICS)
Researchers: Peter Smoak M.S., PhD. Student, School of Exercise and Sport;
Laura K. Stewart, Ph.D., Associate Professor, School of Exercise and Sport Science
Phone: 970-351-1891
PURPOSE AND DESCRIPTION:
Recently it has been suggested that chemotherapy and radiation therapy cause many
negative side effects on the gut microbiome (bacteria in your gut), and in turn, cause
issues with the immune system. It has also been suggested that probiotics may provide
beneficial support to counteract these effects. Accordingly, the specific aim of this project
is to examine the effects of kefir consumption related to the microbiome, gut dysbiosis,
immune function, inflammation and quality of life, fatigue, and depression in cancer
survivors enrolled at the UNCCRI.
SUBJECT INCLUSION:
To be eligible for the kefir or control group, you must be between the ages of 40 and 80
years of age and cancer survivors enrolled in the exercise training program at the
University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI). Also, you
must have undergone chemotherapy or lower body radiation therapy or have undergone
chemotherapy or lower body radiation therapy as a part of your current or past treatment
experience. If you are placed into the kefir group, you must also be willing to drink the
kefir provided. You will not be permitted to participate in the kefir group if they have a
known milk allergy or any allergy to any of the listed ingredients.
If you are ingesting probiotic supplements or foods containing probiotics, you must be
willing to stop using them for 4 weeks prior to enrolling into either the kefir of control
groups in this study. You must also be willing to cease taking thee supplements during
the 12-week training period that you are enrolled in this study.
You will be asked to visit the center six times. During the first 3 visits, basic descriptive
measures including height, weight, waist and hip circumference, and body composition
via bioelectrical impedance (InBody 770 machine) will be obtained as well as aerobic
fitness, measured as VO2peak using the UNCCRI treadmill protocol for VO2peak,
muscular strength, using an estimated 1 Rep Max (1RM) for chest press, shoulder press,
lat pull down, seated row, leg press, leg extension, and leg curl. You will also be asked to
fill out questionnaires related to depression, quality of life, fatigue, physical activity,
dairy and fermented food consumption, and gastric distress, as well as a 3-day dietary log
in which you will record everything eaten during 2 weekdays and 1 weekend, and a 24hour dietary log to assess dietary intake 24 hours prior to the blood draw. Additionally,
you will be asked to provide a resting blood sample that will be analyzed for markers of
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inflammation (C-reactive protein, interleukin-6, and Tumor Necrosis Factor-α) and
immune function and phenotype (classical, non-classical, and intermediate monocytes),
and a fecal sample to analyze your microbiome.
Following the first three visits, you will be asked to follow the structured exercise
regimen established by your trainer at the UNCCRI for twelve weeks. Subjects in the
kefir group will be asked to ingest eight ounces of low fat strawberry banana kefir
(Lifeway Foods, Inc. Morton Grove, IL) within thirty minutes post exercise for twelve
weeks. Subjects in the control group will not be given anything to ingest post exercise
and you will be asked to continue your normal post exercise routine for twelve weeks.
After the twelve-week intervention, you will be asked to return for three additional visits,
which will be identical to your first three visits prior to the 12- week intervention period.
STUDY PROCEDURES
Data collection Procedures
Visit 1 & 4: During initial recruitment visit, you will be asked to review and sign an
informed consent form approved by the Institution Review Board (IRB) at the University
of Northern Colorado, Greeley, CO. You will have an opportunity to review the risks and
benefits of participation as described on the informed consent form. A copy of the
informed consent will be provided to you to keep as a reference. The signed informed
consent form will be stored in a locked filing cabinet at UNCCRI or in Gunter Hall.
After obtaining informed consent and medical history, you will also be asked to fill out
questionnaires related to depression (Beck Inventory), quality of life (Ferrans and
Powers, Cancer Version-III), fatigue (Piper Fatigue Index), physical activity
(International Physical Activity Questionnaire), dairy food intake (dairy consumption
questionnaire), fermented food consumption,(fermented food questionnaire), and gastric
distress (gastric distress survey). In addition to pre and post 12-week intervention period
measures (Visits 1 and 4), the gastric distress survey will be administered once per week
before your exercise regimen at the UNCCRI for the 12-week period to evaluate your
level of discomfort from 0-10 regarding upper gastrointestinal (GI) and lower
gastrointestinal symptoms. Nausea, regurgitation/reflux, and stomach fullness are
indicative of upper GI issues, while abdominal cramps, gas/flatulence, and urge to
defecate are symptoms of lower GI distress.
Aerobic fitness will be measured using the UNCCRI treadmill protocol for VO2 peak.
You will be asked to walk on a treadmill with the speed and grade of the treadmill
increasing every minute. Oxygen saturation and heart rate will be obtained every minute,
and blood pressure and rate of perceived exertion (RPE) will be obtained every three
minutes until the test is complete. The test will be stopped when you reache volitional
fatigue, asks to stop, or the researcher or Clinical Coordinator feels the test must be
terminated.
Additionally, you will be given instructions about the use of a 3-day dietary log in which
you will record everything you consumed during 2 weekdays and 1 weekend day and
return it during the second or third visit.
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Visit 2 & 5: Muscular strength will be assessed using an estimated 1 Rep Max (1RM).
The estimation is based on repetitions to failure that occurs from between 3 to 10
repetitions using the Brzycki equation. Estimated 1RMs will be assessed for all the
following exercises: chest press, shoulder press, lat pull down, seated row, leg press, leg
extension, and leg curl. A fecal sample will be collected to evaluate your microbiome.
You will be given a cotton swab and a resealable bag to collect the fecal sample. When
there is a need to defecate, you will use the cotton swab provided to wipe the used toilet
paper, making sure to fully cover the cotton portion of the swab. Then, place the cotton
swab in the resealable bag. Once this is completed, the bag will need to be placed into a 20 degree freezer as soon as possible.
You will also be provided with instructions to record everything that you eat and drink
during the 24 hours prior to the blood draw in Visits 3 and 6.
Visit 3 & 6: You will return your fecal sample and provide a rested fasted blood sample
(25 mL total: 10 mL serum, 10 mL plasma, 5 mL whole blood) from a prominent
forearm vein. You will need to report to UNCCRI between 0700 and 1000 h following an
overnight fast and having refrained from moderate to vigorous exercise for the previous
72 hours and no exercise for the previous 24 hours. The subjects will be seated quietly for
15 minutes before the blood sample is taken. All blood samples will be collected by a
trained and licensed phlebotomist or nurse at UNCCRI. All samples will be labeled with
subject numerical identifiers. Blood samples will subsequently be analyzed for
biomarkers of inflammation (C-reactive protein, Interleukin-6, Tumor Necrosis Factor-α,
etc.) and immune function and phenotype (classical, non-classical, and intermediate
monocytes).
Additionally, basic descriptive measures including height, weight, waist and hip
circumference, and body composition via bioelectrical impedance (InBody 770 machine)
will be obtained. The bioelectrical impedance measure will involve you standing on a
scale-like platform for no longer than 3 minutes while holding a sensor in each hand.
At the end of Visit 3, you will be asked to follow the structured exercise regimen
established by your trainer at the UNCCRI for twelve weeks. The kefir group will be
asked to ingest 8 ounces of low fat kefir (Lifeway Foods, Inc. Morton Grove, IL) within
thirty minutes post exercise. The control group will not be given anything to ingest post
exercise and will be asked to continue your normal post exercise routine.
Exercise Program:
You will follow the structured exercise regimen established by your trainer 3 times per
week. Each exercise session is 60 minutes in duration and will be split into 3 sections: 20
minutes of aerobic training, 30 minutes of resistance training, and 10 minutes of
stretching and flexibility. Aerobic training can include, but is not limited to, outdoor
walking, cycling, treadmill, arm ergometer, underwater treadmill, or hydrotherapy
treadmill. Resistance training consists of targeting 4 major muscle groups while
incorporating balance into the exercises. The 4 major muscles groups include chest, back,
lower body, and core. Each resistance exercise is performed for 3 sets of 10 repetitions
each. Although all participants in this study will follow the same session structure, the
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intensity of exercises varies depending upon the phase that you are enrolled. Phase 1
participants will perform aerobic exercise at 30-45% of heart rate reserve; resistance
training will be performed at 30-45% of 1RM. These exercises will be performed with a
rate or perceived exertion (RPE) of 1-3. Phase 2 participants will perform aerobic
exercise at 40-60 % of heart rate reserve and resistance training will be performed at 4060% of 1RM. These exercises will be performed with a rate or perceive exertion (RPE) of
3-6.
Dietary Intervention:
You will be assigned to either
the kefir or control group. The
kefir group will be asked to
ingest 8 ounces of low fat
strawberry banana kefir
(Figure 1) (Lifeway Foods,
Inc. Morton Grove, IL) after
each exercise regimen for the
12 weeks. The kefir that will
be consumed contains 12
different strains of probiotics
and 15 - 20 billion colony
forming units (CFU) per 8 oz.
serving. The strains of
probiotics are as follows:
Lactobacillus Lactis,
Lactobacillus Rhamnosus,
Streptococcus Diacetylactis,
Lactobacillus Plantarum,
Lactobacillus Casei,
Saccharomyces Florentinus, Leuconostoc Cremoris, Bifidobacterium Longum,
Bifidobacterium Breve, Lactobacillus Acidophilus, Bifidobacterium Lactis, and
Lactobacillus Reuteri. You will be asked to ingest the kefir within 30 minutes following
each structured exercise bout. If you do not like the taste of the strawberry banana flavor,
you may consume another Lifeway kefir beverage with the same macronutrient and kefir
profile. The kefir consumption will also be monitored by a person on the research team or
a member of the UNCCRI staff. The CON group will not be given anything to ingest post
exercise for the 12-weeks and will be asked to continue their normal post exercise
routine. This approach will simulate the dietary habits of most cancer clients. You will be
asked to complete a post exercise dietary questionnaire both before and after the 12-week
dietary intervention to assess post exercise dietary habits.
Assessments During The Dietary/Control Intervention Time Period:
Prior to each exercise session, you will be asked about exercise and physical activity
outside of your rehabilitation times as well as any changes in medication. Adherence to
the exercise program will be monitored and you will be asked to report feelings of fatigue
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and gastric stress once per week. During each exercise session, heart rate, RPE, blood
pressure, and oxygen saturation will be evaluated.
Microbiome Analysis:
The microbiome analysis of your fecal sample will be carried out by uBiome, a 3rd party
laboratory based in California, and your results will be provided to you by the study
coordinator at UNC. You may elect to create an account with UBiome to have the ability
to review your individualized results through this company. Registering with uBiome
requires you to provide personal information to uBiome. Registration with uBiome is not
a requirement of this project and is not suggested by the UNC research team. If you
choose to sign up for a UBiome account, there will be additional terms and conditions for
which you will have to comply that are outside the protections and oversight of UNC’s
Institutional Review Board.
DATA HANDLING PROCEDURES
Researchers will take a number of precautions in an effort to ensure that your data will
remain confidential unless disclosure is required by law. All data collected will be
handled only by the investigators and kept in a secure location (locked office and filing
cabinet). You will be assigned a numeric identifier and this number will be used on all
written documents and in computer spreadsheets. Only the lead investigator and her
assistants will know the name connected with a subject number and when data is
reported, your name will not be used. Data collected and analyzed for this study will be
kept in a locked cabinet at UNCCRI, which is only accessible by the researcher and her
graduate students.
RISKS, DISCOMFORTS AND BENEFITS
Risks
Participation in this study entails minimal risk.
Blood Draw:
There is a risk of bruising and a remote risk of infection with the blood sampling
techniques. You may also become lightheaded and faint during these procedures. These
risks will be minimized by having trained technicians using sterile, single-use supplies
for blood sampling. You will also be seated during blood sampling.
Exercise:
When exercising, there is a remote risk of a heart attack or stroke and in very rare cases,
death. Also, as with any exercise, there is a chance that that you may experience muscle
soreness, fatigue, or even injuries such as sprains or strains. This will be minimized by
working with trained staff at UNCCRI.
Dietary Intervention:
As with any food, there is a risk of developing an allergy or having an allergic reaction to
the product. This will be minimized by emphasizing all of the beverage components prior
to consumption and asking you to report any negative feelings related to its consumption.
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Discomforts
There may be some minor discomfort associated with the blood draw. You will be seated
comfortably during blood sampling. Any discomfort will be minimized by having trained
technicians perform all blood draws. As with any exercise, there is a chance that that you
may experience muscle soreness or fatigue. With any food that is ingested there may be a
dislike of the food or flavor.
Benefits
While no guarantee of benefits can be made, you will be given body composition analysis
and a dietary and activity assessment at no cost. The researchers will provide you with
your results along with the “normal” ranges for an average, healthy individual at the end
of the study. The researchers will also encourage you to share this information with your
doctor.
COSTS AND COMPENSATION
Costs
There are minimal time and resource related costs to both you and the researcher. The
UNCCRI is located on campus and you will be visiting the UNCCRI as a part of your
normal exercise regimen. The researcher’s office is located in Gunter Hall and is close to
the data collection site.
Compensation
There is no compensation provided to you.
GRANT INFORMATION
This project is funded by the UNC RDFD program (Spring 2018) and UBiome (Summer
2018).
Participation is voluntary. You may decide not to participate in this study and if you
begin participation you may still decide to stop and withdraw at any time. Your decision
will be respected and will not result in loss of benefits to which you are otherwise
entitled. Having read the above and having had an opportunity to ask any questions,
please sign below if you would like to participate in this research. A copy of this form
will be given to you to retain for future reference. If you have any concerns about your
selection or treatment as a research participant, please contact Sherry May, IRB
Administrator, Office of Sponsored Programs, 25 Kepner Hall, University of Northern
Colorado Greeley, CO 80639; 970-351-1910.
Signature of Investigator__________________________________________
Signature of Participant___________________________________________
Date:________________________________
Witness:_____________________________
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24 Hour Diet Log
ID _______________
Breakfast
Food
Amount
Oatmeal –
2% milk
2 packets apple
cinnamon

1 cup
4 oz. Packet

Date: _____________
Meal (include food item and amount)
Lunch
Dinner
Food
Amount
Food
Amount
Chicken SandwichGrilled chicken
Romaine Lettuce
Tomatoes
Light mayonnaise

1 sandwich
4 oz.
2 oz.
2 slices
2Tablespoons

Spaghetti and
meatballsAngel hair pasta
Red sauce
Beef Meatball

1 Plate

Snacks
Food
Amount
Popcorn

2 cooked oz.

3 oz.
3 fluid oz.
2 2oz meatballs
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Gastric Distress Survey
On a scale from 0 to 10. With 0 being no discomfort and 10 being unbearable discomfort
please list your overall level of discomfort for the following:
• Nausea: A feeling of sickness in the stomach marked by an urge to vomit.
• Regurgitation/reflux: Sensation of food or fluid returning from the stomach to the
esophagus or mouth.
• Stomach fullness: A sensation of fullness or abdominal pressure in the upper abdomen.
• Abdominal cramps: Pain or cramping sensation, often experienced in the mid- or
lower-portion of the abdomen.
• Gas/flatulence: Gas or flatus expelled through the anus.
• Urge to defecate: Sensation of needing to pass a bowel movement.
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Supplemental Information
Questionnaire dairy consumption
Instructions
This questionnaire is about dairy products and will be used to make an estimation of the dairy
products you consumed the last month. The following remarks are important and should be
considered during the answering of the questionnaire.
➢ Answer each question as best you can. Estimate if you are not sure. A guess is better than
leaving a blank.
➢ The questions cover the last month, this means the last 4 weeks. This includes both weekdays
and weekends
➢ The products you drank or ate at birthdays, weddings, receptions, etc. should be taken into
account as well.
➢ If you had a completely different diet than normal for example due to illness or holiday for
the last month, consider the month before the last month to fill in the questions.
➢ If you don’t use a product at all, fill in ‘Not this month’. Always give an answer
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1a. How often did you drink milk as a beverage (NOT in coffee, NOT in cereal)? (Please do not
include chocolate milk, hot chocolate and flavored milk or yogurt)
o
o
o
o
o
o
o

Not this month (go to question 2)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

1b. Each day you drank milk as a beverage, how much did you usually drink?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

1c. How often was the milk reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2a. How often did you drink chocolate milk as a beverage (including hot chocolate)?
o
o
o
o
o
o
o

Not this month (go to question 3)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

2b. Each day you drank chocolate milk as a beverage, how much did you usually drink?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

2c. How often was the chocolate milk reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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3a. How often did you drink flavored milks as a beverage?
o
o
o
o
o
o
o

Not this month (go to question 4)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

3b. Each day you drank flavored milks, how much did you usually drink?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

3c. How often was the flavored milk reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

4a. How often did you drink yogurt as a beverage?
o
o
o
o
o
o
o

Not this month (go to question 5)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

4b. Each of the days you drank drink yogurt, how much did you usually drink?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

4c. How often was the yoghurt reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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5a. Do you consume milk with cereals?
o
o
o
o
o
o

Not this month (go to question 6)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week

5b. Each time milk was added to your cold cereal, how much was usually added?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

5c. How often was the milk reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

6a. How often did you eat yogurt?
o
o
o
o
o
o
o

Not this month (go to question 7)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

6b. Each time you ate yogurt, how much did you usually eat?
o
o
o

Less than ½ cup or less than 1 container
0 ½ to 1 cup or 1 container
0 More than 1 cup or more than 1 container

6c. How often was the yogurt you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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7a. How often did you eat cottage cheese?
o
o
o
o
o
o
o

Not this month (go to question 8)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

7b. Each time you ate cottage cheese, how much did you usually eat?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

7c. How often was the cottage cheese you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

8a. How often did you eat pudding or custard?
o
o
o
o
o
o
o

Not this month (go to question 9)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

8b. Each time you ate pudding or custard, how much did you usually eat?
o
o
o

Less than 1 cup (8 ounces)
1-1.5 cups (8 to 12 ounces)
More than 1.5 cups (12 ounces)

8c. How often was the pudding or custard you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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9a. How often did you eat sour cream?
o
o
o
o
o
o
o

Not this month (go to question 10)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

9b. Each time you ate sour cream, how much did you usually eat?
o
o
o

Less than 1 tablespoon
1 to 3 tablespoon
More than 3 tablespoons

9c. How often was the sour-cream you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

10a. How often did you eat cheese (including low-fat; including on cheeseburgers or in
sandwiches or subs)?
o
o
o
o
o
o
o

Not this month (go to question 11)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

10b. Each time you ate cheese, how much did you usually eat?
o
o
o

Less than ½ ounce or less than 1 slice
½ to 1½ ounces or 1 slice
More than 1½ ounces or more than 1 slice

10c. How often was the cheese you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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11a. How often did you eat cream cheese?
o
o
o
o
o
o
o

Not this month (go to question 12)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

11b. Each time you ate cream cheese, how much did you usually eat?
o
o
o

Less than 1 tablespoon
1 to 3 tablespoon
More than 3 tablespoons

11c. How often was the cream cheese you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

12a. How often did you eat whipped cream?
o
o
o
o
o
o
o

Not this month (go to question 13)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week
6-7 days per week

12b. Each time you ate whipped cream, how much did you usually eat?
o
o
o

Less than 1 tablespoon
1 to 3 tablespoon
More than 3 tablespoons

12c. How often was the whipped cream you ate reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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13a. How often do you drink coffee or tea with milk?
o
o
o
o
o
o

Not this month (last question, thank you for completing this questionnaire)
1 day per month or less
2-3 days per month
1 day per week
2-3 days per week
4-5 days per week

13b. Each time milk was added to your coffee or tea, how much was usually added?
o
o
o

Less than 1 tablespoon
1 to 3 tablespoon
More than 3 tablespoons

13 c. How often was the milk reduced-fat or fat-free?
o
o
o
o
o

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

This is the last question, thank you very much for completing this questionnaire
Based on the Diet History Questionnaire, Version 2.0. National Institutes of Health, Applied
Research Program, National Cancer Institute,2010. & the Dutch Dairy Food Frequency
Questionnaire, Wageningen University, Department Human Nutrition, 2005

217

APPENDIX I
FERMENTED FOODS QUESTIONNAIRE

218
Fermented Food Questionnaire
This questionnaire is about fermented food products and will be used to make an estimation of
the fermented food products you consume. Fermented foods can include but are not limited to
fermented milk products such as yogurt and kefir, fermented fruit drinks such as kombucha and
water kefir, and fermented food products such as sauerkraut and kimchee.

Name: ___________________

Client ID: __________________________

1. Have you consumed fermented foods before?
survey, thank you for your time)

□ Yes □ No (If not, this concludes the

2.1 What fermented foods have you consumed (In decreasing order of preference)
Example: Strawberry banana Kefir or

Name

Type
Lifeway

Amount
4 oz.

Sauerkraut

Homemade

3 oz.

2.2 Why did you choose to start consuming fermented foods?

______________________________________________________________________________

______________________________________________________________________________

2.3 Did consumption of fermented foods help?

□ Yes □ No
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3. The consumption frequency and other information
3.1 How often do you consume fermented foods?

□ Once a month □ 1-2 times per month
□ 1-2 times per week □ Almost every day
□ Every day (should be specified)
□ Once a day □ 2 times per day □ 3 times per day □ 4 times per day
□ More than 4 times per day (specify)………………………………………………
3.2 When did you start consuming fermented foods? Month__________________
year_____________
Are you still consuming fermented foods? □ Yes □ No
If no, when did you stop? Month_________________ year_____________
Reason for stopping ___________________________________________________________
Did consumption of fermented foods
3.3 When you started consuming fermented foods, did you have any adverse reactions in the first
week of consumption? (you can choose more than one)

□ Did not have any adverse effects □ Dry mouth or throat □ Drowsiness □ Fever □ Diarrhea
□ Constipation □ Flatulence □ Nausea/vomiting
□ Vertigo □ Rash or itching □ Flushing
□ Anxiety □ Headache □ Edema
□ Insomnia □ Acne, melasma □ Smelled or black stool
□ Other _____________________________________
3.4 Did you have any adverse reactions after the first week of consumption? (you can choose
more than one)

□ Did not have any adverse effects □ Dry mouth or throat □ Drowsiness □ Fever □ Diarrhea
□ Constipation □ Flatulence □ Nausea/vomiting
□ Vertigo □ Rash or itching □ Flushing
□ Anxiety □ Headache □ Edema
□ Insomnia □ Acne, melasma □ Smelled or black stool
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□ Other_____________________________________
If you had an adverse reaction, did you continue or stop consuming fermented foods?

□ Stopped consuming
□ Continued consuming
This concludes the Survey. Thank you for your participation.

